Plasma metabolomic and fecal metagenomic biomarkers for animal growth performance and gut health

The development of plasma and fecal biomarkers, such as alkaline phosphatase and the GH5-p4818Cel5_2A endocellulase gene, addresses the challenge of accurately assessing animal growth performance and gut health, offering a rapid and cost-effective solution for improving animal health monitoring in food animal production.

WO2025050214A1PCT designated stage expired Publication Date: 2025-03-13FAN MING
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
PCT/CA2024/051158
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-09-05
Filing Date
2024-09-05
Publication Date
2025-03-13

AI Technical Summary

Technical Problem

Current methodologies in food animal production are inadequate for accurately and efficiently identifying animal health and growth performance, particularly in animals susceptible to stress and disease challenge, and there is a need for reliable biomarkers to assess gut health and growth performance.

Method used

Development of plasma and fecal biomarkers, including alkaline phosphatase (pALP) and the GH5-p4818Cel5_2A endocellulase gene, which correlate with average daily body weight gain, feed intake, and gut health status, allowing for the prediction and monitoring of animal growth performance and gut health.

Benefits of technology

The proposed biomarkers enable rapid, accurate, and economical monitoring of animal health and growth performance, reducing the reliance on antimicrobials and facilitating early intervention in health issues.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure IMGF000053_0001
    Figure IMGF000053_0001
  • Figure IMGF000061_0001
    Figure IMGF000061_0001
  • Figure IMGF000063_0001
    Figure IMGF000063_0001
Patent Text Reader

Abstract

Disclosed are novel biomarker(s) for assessment and / or prediction of animal gut health, animal growth and / or for development of nutritional and breeding selection strategies for healthy animals. The biomarker(s) comprise metabolomic serum and / or fecal metagenomic biomarkers for assessing / identifying animal growth and gut health status. Method and kits including the biomarker(s) are described
Need to check novelty before this filing date? Find Prior Art

Description

[0001] PLASMA METABOLOMIC AND FECAL METAGENOMIC BIOMARKERS FOR ANIMAL GROWTH PERFORMANCE AND GUT HEALTH Field

[0002] Growth performance, gut health, physiology and welfare assessment of animal health are described. More specifically are developed biomarker(s) for assessment and / or prediction of animal gut health, animal growth and / or for development of nutritional and genetic breeding selection strategies for healthy animals. Methods and kits using the biomarker(s) are described.

[0003] Background

[0004] The gut microbiome plays a crucial role in maintaining nutritional, physiological and immunological functions of hosts such as pigs and humans (Sommer and Backhed, 2013; Guinane and Cotter, 2013; Lu et al., 2018). Gut microbiota, their metabolites and cellular components can regulate host post-digestive route of nutrient utilization and metabolism via an array of pathways such as appetite and voluntary food intake through the enteroendocrine-endocrine-neuronal pathway (Romani-Perez et al., 2021), the host immune system (Rooks and Garrett, 2016) and the host gut non-immune defence factors such as mucin proteins (e.g., MUC2) (Pothuraju et al., 2021) and tight junction proteins (Kaczmarczyk et al., 2021). Perturbations of the gut microbial ecosystem, known as dysbiosis, can predispose the host to various diseases, such as diarrhea, obesity and inflammatory bowel diseases (Carding et al., 2015; Amabebe et al., 2020; Santana et al., 2022).

[0005] With respect to food animal production, pork production contributes to about 35% of the total meat production globally (VanderWaal and Deen, 2018). Weaning of piglets is a critical stage associating with growth retardation, diarrhea and enteric infections, which can lead to morbidity and mortality and thereby negatively influence the efficiency and profitability of pork production (Gresse et al., 2017; Adhikari et al., 2019). Weaning is stressful to weanling pigs due to abrupt dietary, social, and environmental changes that favors the growth of opportunistic pathogenic and zoonotic bacteria, such as enterotoxigenic Escherichia coli (E. coli), Salmonella spp. and Campylobacter spp. (Rhouma et al., 2017; Hahyhoe et al., 2022; Fan et al., 2023) causing gut dysbiosis.

[0006] Food animal production in general incorporates the use of sub-therapeutic and therapeutic levels of antimicrobials for the maintenance of animal health and growth, especially when animals are in the stage that are susceptible to stress and disease challenge (Van Boeckel et al., 2015; Gresse et al., 2017; Fan et al., 2023). The widespread use of antimicrobials such as antibiotics, copper cation and zinc oxide in food animal production however, has contributed to the global public health concern of antimicrobial resistance (Fan and Archbold, 2015; Prestinaci et al., 2015) leading to an increasing number of countries that have banned use of antimicrobials in food production for growth promotion (Van Boeckel et al., Gresse et al. ,2017; Fan et al., 2023)

[0007] The exact mechanisms of antimicrobials in promoting growth are not fully understood however evidence from germ-free animals support interrelations between the host and its gut microbiota (Forbes and Park, 1959; Coates et al., 1963). Antimicrobial-associated growth promotion has been related to improved efficiency of nutrient utilization, i.e. dietary protein and amino acid utilization, by the host (Gaskins et al., 2002; Butaye et al., 2003; Kerr et al., 2022). Further, antimicrobials may directly regulate host gene expression (Gossen and Bujard, 2001; Hill et al., 2021 and mediate non-antimicrobial therapeutic effects via control of target host organ-tissue physiological responses (Bortolanza et al., 2018).

[0008] The gut multi-functional symbiotic bacterial processive endoglycanase gene GH5-p4818Cel5_2A plays a role in fiber degradation and gut health via degrading hemicelluloses and exerting prebiotic effects (Wang et al., 2019) however, its impact on efficiency of digestive utilization of dietary carbohydrates and fat on growth performance in wealings treated with antimicrobials is unknown.

[0009] Gut alkaline phosphatases are involved in the modulation of gut microbiota, thus maintaining gut eubiosis and health (Bates et al., 2007; Fan et al., 2023a). Gut alkaline phosphatases may favor the growth of commensal bacterial population, such as the gram-positive bacteria of Lactobacillaceae (family) and Enterococcus (genus) as well as the commensal gram-negative bacteria of E. Coli, but inhibit the growth of antibiotic- induced pathogenic bacteria, such as Salmonella typhimurium and Clostridium difficile (Malo et al. (2010) and Alam et al. (2014). The process of weaning leads to reduction in gut alkaline phosphatase functionality (Lackeyram et al., 2010). Furthermore, alkaline phosphatases dephosphorylate emblematic members of pathogen-associated-molecular patterns molecules such as the lipopolysaccharides of endotoxin and triphosphate nucleotides in the gut lumen and circulating blood, thus, attenuating gut local and systemic inflammation and metabolic endotoxemia and syndromes (Bates et al., 2007; Kaliannan et al., 2013; Lalies, 2014). Several lines of evidence suggest that pigs, particularly young pigs during weaning transition, experience gut dysbiosis, metabolic endotoxemia and systemic inflammation (Laugerette et al., 2015; Fan et al., 2023a). The role of gut and blood endogenous alkaline phosphatases, as potentially mediated by the antimicrobials, in regulating host gut health and growth performance is unknown in weaning animals, e.g. weanling pigs.

[0010] The foregoing highlights a need to be able to readily identify healthy animals, by growth performance and gut health status in a safe, reliable rapid manner that may be undergoing antimicrobial use.

[0011] Accordingly is a need to be able to readily assess animal gut health and animal growth performance in a substantially rapid, accurate and economical manner based on biophysiological factors especially for animals susceptible to stress and disease challenge. Quantifiable easy-to-measure biomarkers for predicting one or more of body weight gain, feed intake and gut health in animals for use in biomarker assays for both commercial and non-commercial animal production are desired.

[0012] The above discussion is not intended as an admission that any of the foregoing is pertinent prior art.

[0013] Summary

[0014] In view of the foregoing limitations and shortcomings of presently used methodologies in food animal production to identify animal health and growth of animals susceptible to stress and disease challenge and other disadvantages not specifically mentioned above, a more precise and effective approach is desired to identify and select healthy growing animals with a healthy gut microbiome. More specifically to identify biomarkers that are specific for growth performance of an animal, such as a weanling, and that are easily applicable in the field. Further, to identify biomarkers that are specific for predicting overall gut health of an animal, and easily applicable in the field. Still further, to identify biomarkers that are specific for predicting average daily gain, average feed intake and feed conversion efficiency of an animal, and easily applicable in the field. In any of the aspects / embodiments of the invention herein described the animal may be a weanling, and further may be a weanling piglet.

[0015] Further, the pig model as described herein is a reliable large animal model to study general animal and human gut physiology, microbiome, nutrition and disease. Thus the invention described herein has use in developing novel alternative strategies to in aspects, reduce uses of antimicrobials in the animal feed industry, in particular but not limited to the global pork industry. It is understood however, that the invention described herein has use for animals not limited to the animal feed industry.

[0016] Herein described are impacts of therapeutic antimicrobials on the gut health endpoint of fecal score responses and on changes of the efficiency of digestive utilization of dietary nutrients (i.e., starch, crude fat and fiber) including the small intestinal terminal starch digestive enzyme functionality and expression and the gut symbiotic bacterial processive endocellulase GH5-p4818Cel5_2A gene abundance.

[0017] Herein described are impacts of antimicrobials prescription on gut and blood circulating total alkaline phosphatase maximal enzyme activity and endotoxin activity, gut alkaline phosphatase and other host target intestinal gene expression in terms of mRNA abundances as well as the gut health endpoint of fecal score and cecal digesta and fecal endotoxin activity.

[0018] Herein described are impacts of therapeutic antimicrobials on changes of the gut microbiota density, diversity and compositions up to the bacterial species level using the Loop-Seq™ based high-resolution and high-accuracy synthetic full-length 16S-RNA gene sequencing platform.

[0019] Herein described are relationships between the growth performances, gut health and nutrient digestive utilization endpoints and the host physiological factor (i.e., alkaline phosphatases), gut microbiome at bacterial species level and a specific bacterial marker gene (i.e., GH5-p4818Cel5_2A).

[0020] Herein described are physiological factors, the specific bacterial multi-functional processive endocellulase marker gene and fecal bacterial species that serve as effective metabolic and metagenomic biomarkers for predicting growth performances and gut health in weanling pigs.

[0021] In view of the foregoing, the present invention provides for plasma and fecal biomarker(s) useful for identifying and monitoring growth performance and gut health status (fecal score) of animals, in aspects animals used for food animal production or companion animals. In further aspects, the animals are those that may undergo stress and disease challenge. In aspects, the animals may be receiving antimicrobial treatment. In aspects, the animals may experience stress due to weaning. In aspects, the animals are weanlings. In aspects, the animals are pigs. In further aspects, the pigs are weanling pigs.

[0022] The invention allows a farmer (any animal food producer) an improved method for monitoring the health of livestock / animals and help to stay ahead of infective agents and other detrimental changes that can have a profound effect on the animal. This may also help to intervene before antibiotic treatment is required and thus lessen the dependence on antimicrobials. Thus the invention described herein may help to detect / prevent health issues and if required, intervene in a cost and time-effective manner. Further, the biomarkers described herein can be employed for widespread application using substantially non-invasive techniques while providing rapid and accurate results. Biomarkers may be used in conjunction with suitable devices for their rapid analyses, in aspects at their point of testing, for a non-limiting example as dry chemistry tests involving test pads into which chemicals have been impregnated and which react relatively specifically with the biomarker analytes in biofluids, and the results of which can be read by optical or other methods. The analysis can involve simply visual comparison to the color of a reference chart, which is widely employed for the qualitative analysis.

[0023] According to an aspect of the invention is the identification that gut alkaline phosphatases can be used to assess gut health and growth performances in animals, in aspects, animals undergoing stress and / or disease challenge. In aspects weanlings such as weanling pigs.

[0024] According to a further aspect of the invention is the identification of bacterial species that contribute to the host post-digestive route of nutrient utilization and metabolism pathway gene expression under antimicrobial perturbation in animals, in aspects, animals undergoing stress and / or disease challenge. In aspects weanlings such as weanling pigs.

[0025] According to a further aspect of the invention is a method for predicting and / or determining dysbiosis of an animal. In aspects, the animal is a weanling such as weanling piglet. In aspects the animal is receiving antimicrobial treatment.

[0026] According to a further aspect of the invention is the identification of bacterial species responsible for feed intake under antimicrobial perturbation in aspects, animals undergoing stress and / or disease challenge. In aspects weanlings such as weanling pigs.

[0027] According to a further aspect of the invention are methods for identifying and selecting healthy weanling pigs exhibiting desired growth performance.

[0028] According to a further aspect of the invention are methods for identifying and selecting weanling pigs with healthy gut microbiome.

[0029] According to a further aspect of the invention are methods for predicting healthy weanling pigs exhibiting desired growth performance.

[0030] According to a further aspect of the invention are methods for predicting the health of the gut microbiome of weanling pigs.

[0031] According to a further aspect of the invention is a method of monitoring the health performance of an animal comprising collecting a sample from the animal, assaying alkaline phosphatase (pALP) activity as well as plasma, cecal digesta and fecal endotoxin activity, and determining the animal’s relative health performance. In aspects, the animal is a weanling, in further aspects is a weanling piglet. In aspects the sample is plasma.

[0032] According to a further aspect of the invention is a method for determining fecal score (gut health status) comprising collecting a sample from the animal, determining expression levels relative to total 16S rRNA, and determining the animal’s gut health status. In aspects, the animal is a weanling, in further aspects is a weanling piglet. In aspects the sample is a fecal sample. Fecal relative abundances of the GH5- p4818Ce!5_2A endocellulase gene as well as Blautia obeum, Oribacterium sp., Lactobacillus salivarius, p-2534-18B5 sp., dgA-11 sp., Mucispirillum sp. and Streptococcus orisratti serve as biomarkers for predicting porcine gut health. According to a further aspect of the invention is a method for predicting growth performance of an animal comprising collecting a sample from the animal, determining levels of specific fecal bacterial species relative to total 16rRNA genes in the sample, and determining the animal’s growth performance. In aspects the growth performance comprises average daily weight gain, average feed intake and feed conversion efficiency. In aspects, the animal is a weanling, in further aspects is a weanling piglet. In aspects the sample is a fecal sample. In aspects, fecal relative abundances of p-1088- a5 sp., Parasutterella sp., Defluviitaleaceae sp., Parasutterella sp.; Selenomonas sp., Mitsuokella sp., Lachnoclostridium sp. and Streptococcus orisratti serve as non-invasive biomarkers for the prediction of porcine growth performances including daily growth rate, feed intake and feed conversion efficiency.

[0033] According to a further aspect is a composition comprising an isolated metabolomic biomarker consisting essentially of plasma alkaline phosphatase (pALP), wherein the biomarker exhibits a substantial correlation to average daily body weight gain and daily feed intake of an animal. The pALP substantially correlates to jejunal maximal alkaline phosphatase activity. The isolated metabolomic biomarker can be used in the manufacture of a kit for determining average daily body weight gain and daily feed intake of an animal. In aspects, the animal is a weanling. In aspects a weanling piglet.

[0034] According to a further aspect is a composition comprising an isolated metagenomic fecal biomarker consisting essentially of fGH5, wherein the biomarker exhibits a substantial correlation to gut health endpoint of an animal. The fGH5 abundance as a biomarker is relative to total 16S rRNA gene. The isolated metagenomic fecal biomarker can be used in the manufacture of a kit for predicting overall gut health status of an animal. In aspects, the animal is a weanling. In aspects a weanling piglet.

[0035] According to a further aspect is a composition comprising a plurality (in aspects up to about 12 or more) of specific fecal bacterial species as a fecal metagenomic biomarker panel, wherein the biomarker panel exhibits a substantial correlation to gut health status as well as growth performance endpoints of average daily gain, average feed intake and feed conversion efficiency of an animal. The fecal metagenomic biomarker panel can be used in the manufacture of a kit for predicting overall gut health status of an animal. In aspects, the animal is a weanling. In aspects a weanling piglet.

[0036] In aspects of the invention, any of the foregoing compositions can be used in the manufacture of a kit for predicting overall gut health status, growth performance endpoints of average daily gain, average feed intake and feed conversion efficiency of an animal. In aspects, the animal is a weanling. In aspects a weanling piglet.

[0037] In further aspects is a kit for predicting daily body weight gain and daily feed intake in an animal, the kit comprising reagent(s) / substrate(s) for measuring serum pALP activity, and optionally a control sample. The kit may also comprise reagent(s) / substrate(s) for measuring jejunal maximal alkaline phosphatase activity.

[0038] In further aspects is a kit for predicting fecal score in an animal, the kit comprising reagent(s) / substrate(s) for measuring fGH5 abundance (levels), and optionally a control sample. The kit may also comprise reagent(s) / substrate(s) for measuring total 16S rRNA gene abundance / levels.

[0039] In further aspects is a kit for predicting overall gut health status as well as growth performance endpoints of average daily gain, average feed intake and feed conversion efficiency in an animal, the kit comprising reagents for measuring a panel of fecal bacterial species and optionally a control sample.

[0040] In further aspects is a kit comprising a biomarker combination for determining and / or predicting animal growth performance and gut health, the kit comprising: reagent(s) / substrate(s) for measuring serum pALP activity and / or for measuring jejunal maximal alkaline phosphatase activity, and optionally a control sample; reagent(s) / substrate(s) for measuring fGH5 abundance (levels) gene abundance / levels, optionally a control sample; and optional instructions for use.

[0041] The biomarkers of the invention, as compositions or as components of kits, may be commercially based such that they are rapid, accurate and economical for routine monitoring analyses and suitable for use by commercial animal production units.

[0042] Aspects of the invention are not limited to:

[0043] 1. An isolated metabolomic biomarker consisting essentially of plasma alkaline phosphatase (pALP), wherein the biomarker exhibits a substantial correlation to average daily body weight gain and daily feed intake of an animal. 2. The isolated metabolomic biomarker of claim 1, wherein the pALP substantially correlates to jejunal maximal alkaline phosphatase activity of said animal and is predictive of body weight gain and voluntary feed intake of the animal.

[0044] 3. The isolated metabolomic biomarker of claim 1 or 2, for use in in the manufacture of a kit for determining the average daily body weight gain and daily feed intake of the animal.

[0045] 4. The isolated metabolomic biomarker of any one of claims 1 to 3, wherein the animal is susceptible to stress and / or disease challenge.

[0046] 5. The isolated metabolomic biomarker of any one of claims 1 to 4, wherein the animal is a weanling.

[0047] 6. The isolated metabolomic biomarker of claim 5, wherein the animal is a a weanling piglet.

[0048] 7. An isolated metagenomic fecal biomarker consisting essentially of fGH5, wherein the biomarker exhibits a substantial correlation to gut health endpoint of an animal.

[0049] 8. The isolated metagenomic fecal biomarker of claim 7, wherein abundance of fGH5 is determined relative to total 16S rRNA gene.

[0050] 9. The isolated metagenomic fecal biomarker of claim 7 or 8, wherein said biomarker can be used in the manufacture of a kit for predicting overall gut health status of an animal. 10. The isolated metabolomic biomarker of any one of claims 7 to 9, wherein the animal is susceptible to stress and / or disease challenge.

[0051] 11. The isolated metabolomic biomarker of claim 10, wherein the animal is a weanling.

[0052] 12. The isolated metabolomic biomarker of claim 11, wherein the animal is a weanling piglet.

[0053] 13. Specific isolated fecal bacterial species as a fecal metagenomic biomarker panel, wherein the biomarker panel exhibits a substantial correlation to gut health status as well as growth performance endpoints of average daily gain, average feed intake and feed conversion efficiency of an animal. 14. The isolated fecal bacterial species of claim 13 for use in the manufacture of a kit for predicting overall gut health status, growth performance endpoints of average daily gain, and / or average feed intake and feed conversion efficiency of an animal.

[0054] 15. The isolated fecal bacterial species of claim 13 or 14, wherein the animal is a weanling.

[0055] 16. The isolated fecal bacterial species of claim 15, wherein the animal is a weanling piglet.

[0056] 17. The isolated fecal bacterial species of any one of claims 13 to 16, wherein the bacterial species comprises one or more of Blautia obeum, Oribacterium sp., Lactobacillus salivarius, p-2534-18B5 sp., dgA-11 sp., Mucispirillum sp. and Streptococcus orisratti.

[0057] 18. A kit for predicting daily body weight gain and daily feed intake in an animal, the kit comprising reagent(s) / substrate(s) for measuring serum pALP activity.

[0058] 19. A kit for predicting fecal score in an animal, the kit comprising reagent(s) / substrate(s) for measuring fGH5 abundance (levels), and optionally a control sample.

[0059] 20. A kit for predicting overall gut health status as well as growth performance endpoints of average daily gain, average feed intake and feed conversion efficiency in an animal, the kit comprising reagents for measuring a panel of fecal bacterial species and optionally a control sample, wherein the fecal bacterial species comprises at least one of Blautia obeum, Oribacterium sp., Lactobacillus salivarius, p-2534-18B5 sp., dgA-11 sp., Mucispirillum sp. and Streptococcus orisratti.

[0060] 21. A method of monitoring the health performance of an animal comprising collecting a sample from the animal, assaying alkaline phosphatase (pALP) activity as an indication of the animal’s relative health performance.

[0061] 22. A method for determining fecal score (gut health status) comprising collecting a fecal sample from the animal, determining expression levels of GH5-p4818Cel5_2A endocellulase gene relative to total 16S rRNA, and determining / predicting the animal’s gut health status.

[0062] 23. A method for predicting average daily weight gain, average feed intake and feed conversion efficiency of an animal, the method comprising collecting a fecal sample from the animal, determining fecal relative abundances of one or more of Blautia obeum, Oribacterium sp., Lactobacillus salivarius, p-2534-18B5 sp., dgA-11 sp., Mucispirillum sp. and Streptococcus orisratti and determining or predicting the animals gut health.

[0063] 24. A method for predicting growth performance of an animal comprising collecting a fecal sample from the animal, determining levels of specific fecal bacterial species relative to total 16rRNA genes in the sample, and determining the animal’s growth performance.

[0064] 25. The method of claim 24, wherein the growth performance comprises average daily weight gain, average feed intake and feed conversion efficiency.

[0065] 26. The method of claims 24 or 25, wherein the fecal bacterial species are one or more of p-1088-a5 sp., Parasutterella sp., Defluviitaleaceae sp., Parasutterella sp.; Selenomonas sp., Mitsuokella sp., Lachnoclostridium sp. and Streptococcus orisratti.

[0066] 27. The method of any one of claims 21 to 26, wherein the animal is a pig.

[0067] 28. The method of any one of claims 21 to 26, wherein the animal is a weanling.

[0068] 29. The method of any one of claims 21 to 26, wherein the animal is a weanling piglet.

[0069] 30. Use of plasma alkaline phosphatase (pALP) as a serum metabolomic biomarker predictive of average daily body weight gain and daily feed intake of an animal, preferably a weanling piglet.

[0070] 31. Use of fGH5 as a metagenomic fecal biomarker that exhibits a substantial correlation to gut health endpoint of an animal.

[0071] 32. Use of specific fecal bacterial species levels as a metagenomic biomarker panel for predicting overall gut health status of an animal, preferably the fecal bacterial species comprises one or more of p-1088-a5 sp., Parasutterella sp., Defluviitaleaceae sp., Parasutterella sp.; Selenomonas sp., Mitsuokella sp., Lachnoclostridium sp. and Streptococcus orisratti, and preferably the animal is a weanling piglet.

[0072] Still further aspect may comprise:

[0073] 1. A method using a combination of a metabolomic biomarker and a metagenomic biomarker for the assessment and / or monitoring of health performance of an animal, the method comprising: obtaining a physiological sample from the animal, wherein the sample is blood, serum or plasma, and conducting an assay to determine alkaline phosphatase (pALP) activity as the metabolomic biomarker that provides an indication of the animal’s relative health performance.

[0074] 2. The method of aspect 1, wherein the health performance comprises the prediction and / or assessment of average daily weight gain and average feed intake of the animal.

[0075] 3. The method of aspect 1 or 2, wherein the health performance further comprises diagnosis and / or prediction of gut health (fecal score) and feed conversion efficiency in the animal.

[0076] 4. The method of aspect 4, wherein the gut health is determined by collecting a fecal sample from the animal and determining levels of GH5-p4818Cel5_2A endocellulase gene relative to total 16S rRNA.

[0077] 5. The method of aspect 3 or 4, wherein feed conversion efficiency of the animal is performed by determining fecal relative abundances of one or more of Blautia obeum, Oribacterium sp., Lactobacillus salivarius, p-2534-18B5 sp., dgA-11 sp., Mucispirillum sp. and Streptococcus orisratti .

[0078] 6. The method according to any one of aspects 1 to 5, further comprising determining endotoxin activity of plasma, endotoxin activity of cecal digesta and / or fecal endotoxin activity of the animal as a further indicator of health performance of the animal.

[0079] 7. The method according to any one of aspects 1 to 6, wherein the animal is receiving antimicrobial treatment.

[0080] 8. The method according to aspect 7, wherein the health performance is assessed and / or monitored compared to a control animal not receiving antimicrobial treatment.

[0081] 9. The method according to any one of aspects 1 to 8, wherein the animal is undergoing stress and / or disease challenge.

[0082] 10. The method according to any one of aspects 1 to 9, wherein the animal is weaning.

[0083] 11. The method according to any one of aspects 1 to 10, wherein the animal is a livestock animal or a companion animal.

[0084] 12. The method of aspect 11, wherein the animal is a pig.

[0085] 13. The method according to any one of aspects 10 to 12, wherein the animal is a pig or a weaning piglet. 14. A method for identifying and / or monitoring health performance of an animal comprising collecting a sample from the animal, and assaying alkaline phosphatase (pALP) activity as an indication of the animal’s relative health performance.

[0086] 15. The method of aspect 14, wherein the animal is receiving antimicrobial treatment and the pALP activity is increased compared to a control.

[0087] 16. The method of aspect 15, wherein the control is an animal not receiving antimicrobial treatment.

[0088] 17. The method according to aspect 15 or 16, wherein an increase in pALP activity is relative to a control animal, optionally the control animal is receiving antimicrobial treatment.

[0089] 18. A method for determining fecal score (gut health status) comprising collecting a fecal sample from the animal, and determining expression levels of GH5-p4818Cel5_2A endocellulase gene relative to total 16S rRNA, wherein increased expression levels indicate the animal’s gut health status is healthy.

[0090] 19. The method of aspect 18, wherein the animal is receiving antimicrobial treatment and the expression levels are compared to a control.

[0091] 20. The method of aspect 19, wherein the control is an animal not receiving antimicrobial treatment.

[0092] 21. The method according to aspect 19 or 20, wherein an increase in the expression levels of GH5-p4818Cel5_2A endocellulase gene relative to total 16S rRNA, is compared to a control animal, optionally the control animal is receiving antimicrobial treatment.

[0093] 22. A method for predicting average daily weight gain, average feed intake and feed conversion efficiency of an animal, the method comprising collecting a fecal sample from the animal, determining fecal relative abundances of one or more of Blautia obeum, Oribacterium sp., Lactobacillus salivarius, p-2534-18B5 sp., dgA-11 sp., Mucispirillum sp. and Streptococcus orisratti and determining or predicting the animals gut health, wherein increased expression of one or more of Blautia obeum, Oribacterium sp., Lactobacillus salivarius, p-2534-18B5 sp., dgA-11 sp., Mucispirillum sp. and Streptococcus orisratti indicates a healthy animal.

[0094] 23. A method for predicting growth performance of an animal comprising collecting a fecal sample from the animal, determining levels of specific fecal bacterial species relative to total 16rRNA genes in the sample, and determining the animal’s growth performance.

[0095] 24. The method of aspect 23, wherein the growth performance comprises average daily weight gain, average feed intake and feed conversion efficiency.

[0096] 25. The method of aspects 23 or 24, wherein the fecal bacterial species are one or more of p-1088-a5 sp., Parasutterella sp., Defluviitaleaceae sp., Parasutterella sp.;

[0097] Selenomonas sp., Mitsuokella sp., Lachnoclostridium sp. and Streptococcus orisratti.

[0098] 26. The method of any one of aspects 22 to 25, wherein the animal is a pig.

[0099] 27. The method of any one of aspects 22 to 26, wherein the animal is a weanling.

[0100] 28. The method of any one of aspects 22 to 27, wherein the animal is a weanling piglet.

[0101] 29. A component of a kit for determining and monitoring health performance of an animal, the component comprising a means for determining the extent of expression / activity of plasma alkaline phosphatase (pALP) as a metabolomic biomarker for health performance, wherein the alkaline phosphatase activity exhibits a substantial correlation to average daily body weight gain and daily feed intake of an animal as an indication of health performance.

[0102] 30. The component of aspect 29, wherein the pALP substantially correlates to jejunal maximal alkaline phosphatase activity of said animal and is predictive of body weight gain and voluntary feed intake of the animal.

[0103] 31. A component of a kit for determining gut health of an animal, the component comprising a means for determining in a fecal sample from the animal levels of GH5- p4818Cel5_2A endocellulase gene (fGH5) as a biomarker relative to total 16S rRNA, wherein the biomarker exhibits a substantial correlation to gut health endpoint of an animal.

[0104] 32. A fecal metagenomic biomarker panel for assessing gut health of an animal, the panel comprising isolated fecal bacterial species that exhibit a substantial correlation to gut health status as well as growth performance endpoints of average daily gain, average feed intake and feed conversion efficiency of an animal, wherein the bacterial species comprises one or more of Blautia obeum, Oribacterium sp., Lactobacillus salivarius, p-2534-18B5 sp., dgA-11 sp., Mucispirillum sp. and Streptococcus orisratti. 33. A kit for predicting daily body weight gain and daily feed intake in an animal, the kit comprising reagent(s) / substrate(s) for measuring serum pALP activity, and optionally a control sample and / or instructions..

[0105] 34. A kit for predicting fecal score in an animal, the kit comprising: reagent(s) / substrate(s) for measuring fGH5 abundance (levels), and optionally a control sample and / or instructions.

[0106] 35. A kit for predicting overall gut health status as well as growth performance endpoints of average daily gain, average feed intake and feed conversion efficiency in an animal, the kit comprising reagents for measuring a panel of fecal bacterial species and optionally a control sample and / or instructions for use, wherein the fecal bacterial species comprises at least one of Blautia obeum, Oribacterium sp., Lactobacillus salivarius, p-2534-18B5 sp., dgA-11 sp., Mucispirillum sp. and Streptococcus orisratti.

[0107] 30. Use of plasma alkaline phosphatase (pALP) as a serum metabolomic biomarker predictive of average daily body weight gain and daily feed intake of an animal, preferably a weanling piglet.

[0108] 31. Use of fGH5 as a metagenomic fecal biomarker that exhibits a substantial correlation to gut health endpoint of an animal.

[0109] 32. Use of specific fecal bacterial species levels as a metagenomic biomarker panel for predicting overall gut health status of an animal, preferably the fecal bacterial species comprises one or more of p-1088-a5 sp., Parasutterella sp., Defluviitaleaceae sp., Parasutterella sp.; Selenomonas sp., Mitsuokella sp., Lachnoclostridium sp. and Streptococcus orisratti, and preferably the animal is a weanling piglet.

[0110] These and other features, embodiments, and advantages of the present disclosure are mentioned not to limit or define the disclosure, but to provide examples to aid in the understanding thereof when read with the following Description and with reference to the accompanying drawings. Description of the Figures

[0111] Other advantages of the present invention are readily appreciated as the same becomes better understood by reference to the following detailed description when considered in connection with the accompanying drawings wherein:

[0112] Figure 1. Growth performance responses in the weanling pigs fed the experimental diet supplemented with therapeutic antimicrobials in comparison with the control diet for 3 weeks. (A) Average daily gain (ADG, kg-d1); (B) Average daily feed intake (ADFI, kg-d1); and(C) Average daily feed intake to average daily gain ratio (F:G, kg-kg1). Values are presented as least square means (LSMEANS) ± SEM, n = 18 and 16 pens, 5 barrows / pen, in the control and the antimicrobials’ group, respectively. The endpoints homogeneity variances were checked by using the Shapiro-Wilk tests. Differences of the endpoints between the two groups were conducted by the t-test and the two-way ANOVA procedures or the Kruskal-Wallis nonparametric comparisons procedure of SAS with asterisk(s) indicating *, P < 0.05; **, P < 0.01; and ***, P < 0.001, respectively.

[0113] Figure 2. Responses of (A) the fecal score as well as (B) the cecal digesta and the fecal bacterial processive endoglucanase gene GH5-p4818Cel5_2A relative abundance, as determined by the quantitative PCR analyses in the weanling pigs fed the experimental diet supplemented with therapeutic antimicrobials in comparison with the control diet for 3 weeks. Results of the cecal digesta and the fecal bacterial GH5- p4818Cel5_2A gene abundances were normalized using the 16S rRNA gene as a housekeeping control. Data are presented as least square means (LSMEANS) ± SEM; n = 18 and 16 in the control and the antimicrobials’ group, respectively. The endpoints homogeneity variances were checked by using the Shapiro-Wilk tests. Differences of the endpoints between the two groups were conducted by the t-test and the two-way ANOVA procedures or the Kruskal-Wallis nonparametric comparisons procedure of SAS with asterisk(s) indicating *, P < 0.05; **, P < 0.01; and ***, P < 0.001, respectively.

[0114] Figure 3. Responses of (A) the apparent ileal, (B) cecal, (C) total tract and (D) hindgut dry matter (DM) digestibility and (E) the apparent ileal, (F) cecal, (G) total tract and (H) hindgut starch digestibility as well as (I) the total tract crude fat (CF), (J) total tract soluble dietary fiber (SDF), (K) total tract insoluble dietary fiber (IDF) and (L) total tract total dietary fiber (TDF) digestibility values (% of total dietary intake, as-fed basis) in the weanling pigs fed the experimental diet supplemented with therapeutic antimicrobials in comparison with the control diet for 3 weeks. Values are presented as least square means (LSMEANS) ± SEM; at the ileal level, n = 11 and 13 pigs for DM digestibility; n = 4 and 11 pigs for starch digestibility; at the cecal level, n = 17 and 16 pigs for both DM and starch digestibility; at the fecal level, n = 18 and 16 pigs for DM, starch, and CF digestibility; and at the hindgut level, n = 11 and 13 pigs for DM digestibility; n = 4 and 11 pigs for starch digestibility, in the control and the antimicrobials groups, respectively. Net hindgut DM and starch digestibility (%) = Corresponding fecal DM and starch digestibility (%) - Corresponding ileal DM and starch digestibility (%). The endpoint homogeneity variances were checked by using the Shapiro-Wilk tests. Differences of the endpoints between the two groups were conducted by the t-test and the two-way ANOVA procedures or the Kruskal-Wallis nonparametric comparisons procedure of SAS with asterisk(s) indicating *, P < 0.05; **, P < 0.01; and ***, P < 0.001, respectively.KIndicates differences of the endpoints between the two groups were examined by the Kruskal-Wallis nonparametric comparisons procedure of SAS.

[0115] Figure 4. The proximal jejunal and the distal ileal (A) maltase-glucoamylase (MGAM) and (B) sucrase-isomaltase (SI) protein relative abundances measured by the Western blotting analysis as well as the (C) MGAM and (D) SI relative mRNA abundances determined by the real time RT-PCR analyses in the weanling pigs fed the experimental diet supplemented with therapeutic antimicrobials in comparison with the control diet for 3 weeks. Results were normalized using the p-actin as a house-keeping control. Data are presented as least square means and their standard errors (LSMEANS) ± SE; n = 12 and 9 for the jejunal samples for both MGAM and SI protein and mRNA abundances; and n = 13 and 11 for the ileal samples in the control and the antimicrobial groups, respectively, for both MGAM and SI protein and mRNA abundances. The endpoints homogeneity variances were checked by using the Shapiro- Wilk tests. Differences of the endpoints between the two groups were conducted by the t-test and the two-way ANOVA procedures or the Kruskal-Wallis nonparametric comparisons procedure of SAS. Figure 5. Responses of the total alkaline phosphatase (AP) maximal enzyme activity (Vmax, U-mg protein1) in the (A) proximal jejunal, (B) distal ileal, (C) cecal, (D) colonic and (E) plasma (U-mL protein1) and (F) plasma (U-mL plasma1) level as well as the relative abundances of the intestinal alkaline phosphatase (IAP) and the tissue- nonspecific alkaline phosphatase (TNAP) gene mRNA determined by the real time RT- PCR analyses in the (G) proximal jejunal, (H) distal ileal, (I) cecal and (J) colonic level in the weanling pigs fed the experimental diet supplemented with therapeutic antimicrobials in comparison with the control diet for 3 weeks. Results of the IAP and TNAP mRNA abundances were normalized using the p-actin as a house-keeping control. Data are presented as least square means and their standard errors (LSMEANS) ± SE; at the jejunal level, n = 12 and 9 pigs for both AP- Vmaxand mRNA abundances; at the ileal level, n = 13 and 11 for both AP- Vmaxand mRNA abundances; at the cecal level, n = 15 and 14 pigs for both AP Vmaxand mRNA abundances; at the colonic level, n = 16 and 15 for AP- Vmax, and n = 17 and 15 for mRNA abundances; and at the plasma level, n = 17 and 16 for AP- Vmaxin the control and the antimicrobials groups, respectively. The endpoints homogeneity variances were checked by using the Shapiro-Wilk tests. Differences of the endpoints between the two groups were conducted by the t-test and the two-way ANOVA procedures or the Kruskal-Wallis nonparametric comparisons procedure of SAS with asterisk(s) indicating *, P < 0.05; **, P < 0.01; and ***, P < 0.001, respectively.KIndicates difference of the endpoint between the two groups was examined by the Kruskal-Wallis nonparametric comparisons procedure of SAS. U, mg-min1.

[0116] Figure 6. Comparisons of the maximal enzyme activity (Vmax, U-mg protein1) of the total alkaline phosphatase (A) among the plasma and different gut tissues expressed in U-mg protein1and (B) among the plasma and different gut tissues expressed in U-mg protein1or in U-mL plasma1as well as (C) comparisons of the mRNA relative abundances (in arbitrary units) of the intestinal alkaline phosphatase (IAP) (C) and the tissue-nonspecific alkaline phosphatase (TNAP) (D) among different gut tissues in the weanling pigs fed the experimental diet supplemented with therapeutic antimicrobials in comparison with the control diet for 3 weeks. Data are presented as least square means and their standard errors (LSMEANS) ± SE; and the same number of observations as indicated in Fig. 5. Columns with different letters within the same experimental group were significantly different (P < 0.05) according to Tukey's multiple comparisons test of SAS.

[0117] Figure 7. Comparisons of the endotoxin activity (EU) in feces (A) on as-fed basis; (B) on dry matter (DM) basis and (C) on basis of per kg DM diet intake in the weanling pigs fed the experimental diet supplemented with therapeutic antimicrobials in comparison with the control diet for 3 weeks. Because of abnormality of the original data, log-transformations were performed and ANOVA were carried out with log- transformed data. Thus, data are presented as back-transformed least square mean (BTLSMEAN) and back-transformed standard error (BTSE) for the mean (BTLSMEAN ± BTSE); n = 13 and n = 10 pigs, in the control and the antimicrobials groups, respectively.

[0118] Figure 8. Comparisons of the endotoxin activity (EU) in (A) blood plasma; (B) cecal digesta on fresh basis and (C) cecal digesta on dry matter (DM) basis in the weanling pigs fed the experimental diet supplemented with therapeutic antimicrobials in comparison with the control diet for 3 weeks. Because of abnormality of the original data, log-transformations were performed and ANOVA were carried out with log- transformed data. Thus, data are presented as back-transformed least square mean (BTLSMEAN) and back-transformed standard error (BTSE) for the mean (BTLSMEAN ± BTSE); n = 19 and n = 16 pigs for the plasma; and n = 13 and n = 10 pigs for the cecal digesta, in the control and the antimicrobials groups, respectively.

[0119] Figure 9. Antimicrobials in regulation of the relative mRNA abundances determined by the real-time RT-PCR analyses for the appetite control genes of (A) Proglucagon and (B) PYY; gut permeability genes of (C) MUC2, (D) ZO-1, (E) Claudin-1, (F) Claudin-3 and (G) Occludin; inflammation master control genes of (H) TLR4, (I) NF- KB and (J) FOXP3; anti-inflammatory cytokine genes of (K) TGF-P and (L) IL-10; and the pro-inflammatory cytokine genes of (M) TNF-a and (N) IL-1 p along the small-large intestinal longitudinal axis in the weanling pigs fed the experimental diets for 3 weeks. Results were normalized using the p-actin as a house-keeping control. Data are presented as least square means and their standard errors (LSMEAN ± SE); n = 12 and 9 for the jejunal samples; n = 13 and 11 for the ileal samples; n = 15 and 14 for the cecal samples; and n = 17 and 15 for the colonic samples in the control and the antimicrobials groups, respectively. The endpoints homogeneity variances were checked by using the Shapiro-Wilk tests. Differences of the endpoints between the two groups were conducted by the t-test and the two-way ANOVA procedures or the Kruskal-Wallis nonparametric comparisons procedure of SAS with asterisk(s) indicating *, P < 0.05; **, P < 0.01; and ***, P < 0.001, respectively, indicates difference of the endpoint between the two groups was examined by the Kruskal-Wallis nonparametric comparisons procedure of SAS.

[0120] Figure 10. Rarefaction curve relationships between number of identified non- redundant denoised amplicon sequence variants (ASV) and numbers of the cecal digesta (A) and (B) and the fecal (C) and (D) metagenomic DNA samples obtained from the weanling pigs fed the experimental diet supplemented with therapeutic antimicrobials in comparison with the control diet for 3 weeks.

[0121] Figure 11. Rarefaction curve relationships between the number of identified non-redundant denoised amplicon sequence variants (ASV) and the number of 1.5-kb amplicon DNA molecules (for up to 18 x 12,000 = 216,000 for the control group vs. = 16 x 12,000 = 192,000 for the antimicrobials’ group) sequenced and assembled via the LoopSeq™ long-read platform from (A) the cecal digesta and (B) the fecal metagenomic DNA samples; as well as the extrapolated rarefaction plateau non-redundant denoised ASV values assessed by using Bootstrapping, Chao, and Jackknife estimators for (C) the cecal digesta and (D) the fecal metagenomic DNA samples in the weanling pigs fed the experimental diet supplemented with therapeutic antimicrobials in comparison with the control diet for 3 weeks. Data are presented as least square means and their standard errors (LSMEANS ± SE); n = 18 and 16 pigs in the control and the antimicrobials’ group, respectively, for both the cecal digesta and the fecal samples. Comparisons for the endpoints of the Bootstrapping, Chao, and Jackknife estimators between the control and the antimicrobials’ groups were conducted by using the unpaired pooled t- tests in GraphPad Prism with asterisk(s) indicating **, P < 0.01; and ***, P < 0.001, respectively.

[0122] Figure 12. The cecal digesta (A) and (B) and the fecal (C) and (D) bacterial alpha-diversity endpoints of the Simpson index, the Shannon index; and the Chao 1 index; as well as (E) the cecal digesta and (F) the fecal bacterial beta-diversity endpoint of the principal component analysis (PCA) in the weanling pigs fed the experimental diet supplemented with therapeutic antimicrobials in comparison with the control diet for 3 weeks. alpha-Diversity endpoints are presented as least square means and their standard errors (LSMEANS ± SE); n = 18 and 16 pigs in the control and the antimicrobials groups, respectively, for both the cecal digesta and the fecal samples. The endpoints homogeneity variances were checked by using the Shapiro-Wilk tests. Differences of the endpoints between the two groups were conducted by the t-test and the two-way ANOVA procedures or the Kruskal-Wallis nonparametric comparisons procedure of SAS with asterisk(s) indicating *, P < 0.05; **, P < 0.01; and ***, P < 0.001, respectively, indicates differences of the endpoints between the two groups were examined by the Kruskal-Wallis nonparametric comparisons procedure of SAS.

[0123] Figure 13. The cecal digesta (A) and the fecal (B) bacterial relative abundances (% of the total) at the species level being significantly modulated by the antimicrobials in the weanling pigs fed the experimental diet supplemented with therapeutic antimicrobials in comparison with the control diet for 3 weeks. Data are presented as least square means and their standard errors (LSMEANS ± SE); n = 18 and 16 pigs in the control and the antimicrobials groups, respectively, for both the cecal digesta and the fecal samples. The endpoints homogeneity variances were checked by using the Shapiro-Wilk tests. Differences of the endpoints between the two groups were conducted by the t-test and the two-way ANOVA procedures or the Kruskal-Wallis nonparametric comparisons procedure of SAS with asterisk(s) indicating *, P < 0.05; **, P < 0.01; and ***, P < 0.001, respectively, indicates differences of the endpoints between the two groups were examined by the Kruskal-Wallis nonparametric comparisons procedure of SAS.

[0124] Figure 14. Heat maps showing Spearman’s correlations between the growth performance endpoints of the 3-wk final body weight (BW, kg; n = 34), average daily gain (ADG, kg-d1; n = 34), average feed intake (ADFI, kg-d1; n = 34), and feed to gain ratio (F:G, kg-kg1; n = 34); and 3-wk average daily gain (ADG, kg-d1; n = 34), average feed intake (ADFI, kg-d1; n = 34), nutritional endpoints of fecal dry matter (DM) digestibility (%; n = 34), hindgut DM digestibility (% of total dietary intake; n = 24), cecal DM digestibility (%; n = 33), ileal DM digestibility (%; n = 24), fecal starch digestibility (%; n = 34), hindgut starch digestibility (%; n = 15), cecal starch digestibility (%; n = 33), ileal starch digestibility (%; n = 15), fecal crude fat digestibility (%; n = 34), fecal insoluble dietary fiber (IDF) digestibility (%; n = 34), fecal soluble dietary fiber (SDF) digestibility (%; n = 34), fecal total dietary fiber (TDF) digestibility (%; n = 34), biochemical endpoints of the jejunal (n = 21) and the ileal (n = 24) maltose-hydrolytic kinetic affinity (Km, mmol-L1) and the maximal enzyme activity (Vmax, nmol-mg protein- ’•min-1), jejunal (n = 21) and ileal (n = 24) sucrose-hydrolytic kinetic Km( mmol-L-1) and Vmax(nmol-mg protein-1-min-1); as well as molecular endpoints of the jejunal (n = 21) and the ileal (n = 24) maltase-glucoamylase (MGAM) protein and mRNA relative abundances (in arbitrary units) and the jejunal (n = 21) and the ileal (n = 24) sucrase- isomaltase (SI) protein and mRNA relative abundances (in arbitrary units) (A) within the control group; (B) within the antimicrobials groups; and (C) across the control and the antimicrobials groups in the weanling pigs fed the experimental diet supplemented with therapeutic multi-antimicrobials in comparison with the control diet for 3 weeks. The color depth represents the strength and level (rvalue) of the correlations. *P < 0.05; **P < 0.01; and ***p < 0.001 vs. no significant differences (P > 0.05) and / or a trend of differences (P = < 0.10) for the endpoints, as analyzed by using the SAS.

[0125] Figure 15. Heat maps showing Spearman’s correlations between the nutritional endpoints of the fecal insoluble dietary fiber (IDF) digestibility (% of total dietary intake; n = 34), fecal soluble dietary fiber (SDF) digestibility (%; n = 34) and the fecal total dietary fiber (TDF) digestibility (%; n = 34); and the other nutritional endpoints of fecal dry matter (DM) digestibility (%; n = 34), hindgut DM digestibility (%; n = 24), cecal DM digestibility (%; n = 33), ileal DM digestibility (%; n = 24), fecal starch digestibility (%; n = 34), hindgut starch digestibility (%; n = 15), cecal starch digestibility (%; n = 33), ileal starch digestibility (%; n = 15), fecal crude fat digestibility (%; n = 34) (A) within the control group; (B) within the antimicrobials’ group; and (C) across the control and the antimicrobials groups as well as (D) the Spearman’s correlations between the nutritional endpoints of fecal starch digestibility (%; n = 34), hindgut starch digestibility (%; n = 15), cecal starch digestibility (%; n = 33), and ileal starch digestibility (%; n = 15); and the biochemical endpoints of jejunal (n = 21) and ileal (n = 24) maltose-hydrolytic kinetic affinity (Km, mmol-L-1) and the maximal activity (Vmax, nmol-mg protein-1-min-1), jejunal (n = 21) and ileal (n = 24) sucrose-hydrolytic kinetic Km( mmol-L-1) and Vmax(nmol-mg protein-1-min-1), as well as molecular endpoints of jejunal (n = 21) and ileal (n = 24) maltase-glucoamylase (MGAM) protein and mRNA relative abundances (in arbitrary units) and jejunal (n = 21) and ileal (n = 24) sucrase-isomaltase (SI) protein and mRNA relative abundances (in arbitrary units) across the control and the antimicrobials groups in the weanling pigs fed the experimental diet supplemented with therapeutic multiantimicrobials in comparison with the control diet for 3 weeks. The color depth represents the strength and level (rvalue) of the correlations. *P < 0.05; **P < 0.01; and ***P < 0.001 vs. no significant differences (P > 0.05) and / or a trend of differences (P =

[0126] < 0.10) for the endpoints, as analyzed by using the SAS.

[0127] Figure 16. Heat maps showing Spearman’s correlations between the cecal digesta (A), (B), (C), and (D) and the fecal (E), (F), (G), and (H) microbiome endpoints of bacterial density (bacterial density, trillions-kg DM digesta1; n = 34), alpha-bacterial diversity endpoints (n = 34) of Shannon index, Simpson index, and Chaol index and relative abundances (%; n = 34) of the significantly affected bacterial species; and the growth performance and nutritional endpoints of the 3-wk final body weight (BW, kg; n = 34), average daily gain (ADG, kg-d1; n = 34), average feed intake (ADFI, kg-d1; n = 34), and feed to gain ratio (F:G, kg-kg1; n = 34), fecal dry matter (DM) digestibility (%; n = 34), hindgut DM digestibility (%; n = 24), cecal DM digestibility (%; n = 33), ileal DM digestibility (%; n = 24); and the fecal starch digestibility (%; n = 34), hindgut starch digestibility (%; n = 15), cecal starch digestibility (%; n = 33), ileal starch digestibility (%; n = 15), fecal crude fat digestibility (%; n = 34), fecal insoluble dietary fiber (IDF) digestibility (%; n = 34), fecal soluble dietary fiber (SDF) digestibility (%; n = 34), fecal total dietary fiber (TDF) digestibility (%; n = 34); and the biochemical endpoints of the jejunal (n = 21) and the ileal (n = 24) maltose-hydrolytic kinetic affinity (Km, mmol-L1) and the maximal activity (Vmax, nmol-mg protein '-min1), and the jejunal (n = 21) and the ileal (n = 24) sucrose-hydrolytic kinetic Km( mmol-L1) and Vmax(nmol-mg protein '-min1) at the cecal digesta and the fecal levels; and the molecular endpoints of jejunal (n = 21) and ileal (n = 24) maltase-glucoamylase (MGAM) protein and mRNA relative abundances (in arbitrary units), and jejunal (n = 21) and ileal (n = 24) sucrase-isomaltase (SI) protein and mRNA relative abundances (in arbitrary units) at the cecal digesta and the fecal levels in the weanling pigs fed the experimental diet supplemented with therapeutic multi-antimicrobials in comparison with the control diet for 3 weeks. The color depth represents the strength and level (rvalue) of the correlations. *P < 0.05; **P

[0128] < 0.01; and ***p < 0.001 vs. no significant differences (P > 0.05) and / or a trend of differences (P = < 0.10) for the endpoints, as analyzed by using the SAS. Figure 17. Heat map showing Spearman’s correlations between the growth performance endpoints of the 3-wk final body weight (BW, kg; n = 34), average daily gain (ADG, kg-d1; n = 34), average feed intake (ADFI, kg-d1; n = 34), and feed to gain ratio (F:G, kg-kg1; n = 34), and the gut health endpoint of fecal score (in arbitrary ranking unit; n = 34) as well as the nutritional endpoints of ileal dry matter (DM) digestibility (%; n = 24), cecal DM digestibility (%; n = 33), hindgut DM digestibility (%; n = 24), fecal DM digestibility (%; n = 34), ileal starch digestibility (%; n = 15), cecal starch digestibility (%; n = 33), hindgut starch digestibility (%; n = 15), the fecal starch digestibility (%; n = 34), fecal crude fat digestibility (%; n = 34), fecal insoluble dietary fiber (IDF) digestibility (%; n = 34), fecal soluble dietary fiber (SDF) digestibility (%; n = 34), and fecal total dietary fiber (TDF) digestibility (%; n = 34); and the total alkaline phosphatase (AP) kinetics of the maximal enzyme activity ( Vmax) endpoints of the plasma AP- Vmax(U-mg protein1; n = 33), plasma AP-I / ,„„y(U-mL plasma1; n = 33), jejunal AP- Vmax(U-mg protein1; n = 21), ileal AP-I / ,„„y(U-mg protein1; n = 24), cecal AP- Vmax(U-mg protein1; n = 29), and colonic AP-I / ,„„y(U-mg protein1; n = 31) as well as the plasma total volatile sulfides (mg-mL plasma1; n = 34), plasma indole (mg-mL plasma1; n = 34), and plasma indole analogs (mg-mL plasma1; n = 34) across the control and the antimicrobials groups in the weanling pigs fed the experimental diet supplemented with therapeutic multi-antimicrobials in comparison with the control diet for 3 weeks. The color depth represents the strength and level (rvalue) of the correlations. *P < 0.05; **P < 0.01; and ***p < 0.001 vs. no significant differences (P > 0.05) and / or a trend of differences (P = < 0.10) for the endpoints, as analyzed by using the SAS. U, mg-min1.

[0129] Figure 18. Heat maps showing Spearman’s correlations between the ileal digesta (A) microbiome endpoint of the relative abundances (% of the total; n = 17) of the significantly affected bacterial species as well as the cecal digesta (B) and the fecal (C) microbiome endpoints of the corresponding cecal and fecal relative abundances of bacterial GH5-p4818Cel5_2A (in arbitrary units; n = 34), bacterial density (trillions-kg DM digesta1; n = 34), alpha-bacterial diversity endpoints (n = 34) of Shannon index, Simpson index, and Chaol index and relative abundances (%; n = 34) of the significantly affected bacterial species; and the total alkaline phosphatase (AP) kinetics of the maximal enzyme activity (Vmax) endpoints of the plasma AP-I / ,„„y(U-mg protein1; n = 33), plasma AP-I / ,„„y(U-mL plasma1; n = 33), jejunal AP-I / ,„„y(U-mg protein1; n = 21), ileal AP-I / ,„„y(U-mg protein1; n = 24), cecal AP-I / ,„„y(U-mg protein1; n = 29), and colonic AP-I / ,„„y(U-mg protein1; n = 31) as well as the gut health endpoint of fecal score (in arbitrary ranking unit; n = 34) across the control and the antimicrobials’ groups in the weanling pigs fed the experimental diet supplemented with therapeutic multiantimicrobials in comparison with the control diet for 3 weeks. The color depth represents the strength and level (rvalue) of the correlations. *P < 0.05; **P < 0.01; and ***P < 0.001 vs. no significant differences (P > 0.05) and / or a trend of differences (P = < 0.10) for the endpoints, as analyzed by using the SAS. U, mg-min1.

[0130] Figure 19. Heat map showing Spearman’s correlations between the growth performance endpoints of the 3-wk final body weight (BW, kg; n = 34), average daily gain (ADG, kg-d1; n = 34), average feed intake (ADFI, kg-d1; n = 34), and feed to gain ratio (F:G, kg-kg1; n = 34), as well as the gut health endpoint of fecal score (in arbitrary ranking unit; n = 34); and the relative mRNA abundances (in arbitrary units) of the host genes including appetite control genes of proglucagon and PYY; gut permeability genes of MUC2, ZO-1, Claudin-1, Claudin-3, and Occludin; inflammation master control genes of TLR4, NF-KB, and FOXP3; anti-inflammatory cytokine genes of TGF-P and IL-10; and pro-inflammatory genes of TNF-a and IL-1 p at the (A) proximal jejunal (n = 21); (B) distal ileal (n = 24); (C) cecal (n = 29); and (D) colonic (n = 32) tissue homogenates in the weanling pigs fed the experimental control diet and treatment diet administered with therapeutic multi-antimicrobials for 3 weeks. The color depth represents the strength and level (rvalue) of the correlations. *P < 0.05; **P < 0.01; and ***p < 0.001 vs. no significant differences (P > 0.05) and / or a trend of differences (P = < 0.10) for the endpoints, as analyzed by using the SAS.

[0131] Figure 20. Heat maps showing Spearman’s correlations between the jejunal relative mRNA abundances (in arbitrary units; n = 21) of the host genes including appetite control genes of proglucagon and PYY; gut permeability genes of MUC2, ZO-1, Claudin-1, Claudin-3, and Occludin; inflammation master control genes of TLR4, NF-KB, and FOXP3; anti-inflammatory cytokine genes of TGF-P and IL-10; and pro- inflammatory cytokine genes of TNF-a and IL-1 p and the distal ileal digesta microbiome endpoints of the relative abundances (%; n = 17) of the significantly affected bacterial species in the weanling pigs fed the experimental control diet and the treatment diet administered with therapeutic antimicrobials for 3 weeks. The color depth represents the strength and level (rvalue) of the correlations. *P < 0.05; **P < 0.01; and ***p < 0.001 vs. no significant differences (P > 0.05) and / or a trend of differences (P = < 0.10) for the endpoints, as analyzed by using the SAS.

[0132] Figure 21. Heat maps showing Spearman’s correlations between the distal ileal relative mRNA abundances (in arbitrary units; n = 24) of the host genes including appetite control genes of proglucagon and PYY; gut permeability genes of MUC2, ZO-1, Claudin-1, Claudin-3, and Occludin; inflammation master control genes of TLR4, NF-KB, and FOXP3; anti-inflammatory cytokine genes of TGF-P and IL-10; and antiinflammatory genes of TNF-a and IL-1 p and the distal ileal digesta microbiome endpoint of the relative abundances (%; n = 17) of the significantly affected bacterial species in the weanling pigs fed the experimental control diet and the treatment diet administered with therapeutic multi-antimicrobials for 3 weeks. The color depth represents the strength and level (rvalue) of the correlations. *P < 0.05; **P < 0.01; and ***P < 0.001 vs. no significant differences (P > 0.05) and / or a trend of differences (P = < 0.10) for the endpoints, as analyzed by using the SAS.

[0133] Figure 22. Heat maps showing Spearman’s correlations between the cecal relative mRNA abundances (in arbitrary units; n = 29) of the host genes including appetite control genes of proglucagon and PYY; gut permeability genes of MUC2, ZO-1, Claudin-1, Claudin-3, and Occludin; inflammation master control genes of TLR4, NF-KB, and FOXP3; anti-inflammatory endpoint genes of TGF-P and IL-10; and pro- inflammatory genes of TNF-a and IL-1 p and the cecal digesta microbiome endpoints of the cecal relative abundances of the bacterial gene GH5-p4818Cel5_2A (in arbitrary units; n = 34), bacterial density (trillions-kg DM digesta-1; n = 34), alpha-bacterial diversity endpoints (n = 34) of Shannon index, Simpson index, and Chaol index and relative abundances (%; n = 34) of the significantly affected bacterial species in the weanling pigs fed the experimental control diet and the treatment diet administered with therapeutic multi-antimicrobials for 3 weeks. The color depth represents the strength and level (rvalue) of the correlations. *P < 0.05; **P < 0.01; and ***p < 0.001 vs. no significant differences (P > 0.05) and / or a trend of differences (P = < 0.10) for the endpoints, as analyzed by using the SAS.

[0134] Figure 23. Heat maps showing Spearman’s correlations between the colonic relative mRNA abundances (in arbitrary units; n = 32) of the host genes including appetite control genes of proglucagon and PYY; gut permeability genes of MUC2, ZO-1, Claudin-1, Claudin-3, and Occludin; inflammation master control genes of TLR4, NF-KB, and FOXP3; anti-inflammatory genes of TGF-P and IL-10; and pro-inflammatory genes of TNF-a and IL-1 p and the fecal digesta microbiome endpoints of the fecal relative abundances of bacterial GH5-p4818Cel5_2A (in arbitrary units; n = 34), bacterial density (trillions-kg DM digesta-1; n = 34), alpha-bacterial diversity endpoints (n = 34) of Shannon index, Simpson index, and Chaol index and relative abundances (%; n = 34) of the significantly affected bacterial species in the weanling pigs fed the experimental control diet and the treatment diet administered with therapeutic multi-antimicrobials for 3 weeks. The color depth represents the strength and level (rvalue) of the correlations. *P < 0.05; **P < 0.01; and ***p < 0.001 vs. no significant differences (P > 0.05) and / or a trend of differences (P = < 0.10) for the endpoints, as analyzed by using the SAS.

[0135] Figure 24. The linear relationships (parameter estimates ± SE, shown below, respectively) between growth performance responses [y axis, mean ± SE, n = 34] and the significantly correlated fecal bacterial species (x axis, mean ± SE, n = 34) in the weanling pigs fed the experimental diet supplemented with therapeutic multiantimicrobials in comparison with the control diet for 3 weeks. (A) Linear plot between ADG (mean ± SE, n = 34, kg-d1) and bacterial species p-1088-a5 sp. (mean ± SE, n = 34, %) according to a simple linear response model as: y = -0.9614 (± 0.3218)x + 0.3305 (± 0.00737), Aiope = 0.0054; and Pntercept < 0.0001; r2= 0.2181, n = 34; (B) Linear plot between ADG (mean ± SE, n = 34, kg-d1) and bacterial species Parasutterella sp. (mean ± SE, n = 34, %) according to a simple linear response model as: y = 1.9101 (± 0.6604)x + 0.3054 (± 0.00758), Psiope = 0.0068; and Pntercept < 0.0001; r2= 0.2072, n = 34; (C) Linear plot between ADFI (mean ± SE, n = 34, kg-d1) and bacterial species Defluviitaleaceae sp. (mean ± SE, n = 34, %) according to a simple linear response model as: y = 2.1731 (± 0.8234)x + 0.4142 (± 0.00906), Piope = 0.0127; and Pntercept < 0.0001; r2= 0.1787, n = 34; (D) Linear plot between ADFI (mean ± SE, n = 34, kg-d1) and bacterial species Parasutterella sp. (mean ± SE, n = 34, %) according to a simple linear response model as: y = 2.2437 (± 0.8056)x + 0.4123 (± 0.00924), Ps\ove= 0.0089; and ^intercept < 0.0001; r2= 0.1951, n = 34; (E) Linear plot between F:G (mean ± SE, n = 34, kg-kg1) and bacterial species Selenomonas sp. (mean ± SE, n = 34, %) according to a simple linear response model as: y = 0.1128 (± 0.0280)x + 1.2871 (± 0.0202), Pslope= 0.0003; and Pintercept< 0.0001; r2= 0.3369, n = 34; (F) Linear plot between F:G (mean ± SE, n = 34, kg·kg-1) and bacterial species Mitsuokella sp. (mean ± SE, n = 34, %) according to a simple linear response model as: y = 0.1838 (± 0.0669)x + 1.3052 (± 0.0215), Pslope= 0.0097; and Pintercept< 0.0001; r2= 0.1910, n = 34; (G) Linear plot between F:G (mean ± SE, n = 34, kg·kg-1) and bacterial species Lachnoclostridium sp. (mean ± SE, n = 34, %) according to a simple linear response model as: y = 0.7285 (±0.2334)x + 1.2678 (± 0.0295), Pslope= 0.0038; and Pintercept< 0.0001; r2= 0.2334, n = 34; (H) Linear plot between F:G (mean ± SE, n = 34, kg·kg-1) and bacterial species Streptococcus orisratti (mean ± SE, n = 34, %) according to a simple linear response model as: y = 3.8406 (±1.4221)x + 1.3297 (± 0.0163), Pslope= 0.0110; and Pintercept< 0.0001; r2= 0.1856, n = 34. The linear response models were visualized and plotted using GraphPad Prism. The linear regression analyses were conducted with the NLIN procedures in SAS. Significance level at P < 0.05 was used for all the parameter estimates. ADG, average daily gain; ADFI, average daily feed intake; and F:G, average daily feed intake to average daily gain ratio. Figure 25. The linear relationships (parameter estimates ± SE, shown below, respectively) between the growth performance responses [y axis, mean ± SE, n = 34] and the plasma total alkaline phosphatase (AP) maximal activity (Vmax) (x axis, mean ± SE, n = 33) as well as the linear relationships (parameter estimates ± SE, shown below, respectively) between the gut health response fecal score [y axis, mean ± SE, n = 34] and the cecal digesta and fecal relative abundances of bacterial GH5-p4818Cel5_2A (x axis, mean ± SE, n = 34) as well as the significantly correlated fecal bacterial species (x axis, mean ± SE, n = 34) in the weanling pigs fed the experimental diet supplemented with therapeutic multi-antimicrobials in comparison with the control diet for 3 weeks. (A) Linear plot between ADG (mean ± SE, n = 34, kg·d-1) and plasma AP Vmax(mean ± SE, n = 33, U·mL plasma-1) according to a simple linear response model as: y = 0.0043 (± 0.00192)x + 0.2710 (± 0.0217), Pslope= 0.0320; and Pintercept< 0.0001; r2= 0.1504, n = 33; (B) Linear plot between ADFI (mean ± SE, n = 34, kg·d-1) and plasma AP Vmax(mean ± SE, n = 33, U·mL plasma-1) according to a simple linear response model as: y = 0.00534 (± 0.00230) x + 0.3685 (± 0.0260), Pslope= 0.0267; and Pintercept< 0.0001; r2= 0.1668, n = 33; (C) Linear plot between fecal score (mean ± SE, n = 34, in arbitrary ranking unit) and cecal bacterial GH5-p4818Cel5_2A abundance (mean ± SE, n = 34, in arbitrary unit) according to a simple linear response model as: y = -0.00612 (± 0.00259) x + 0.6935 (± 0.0414), Pslope= 0.0246; and Pintercept< 0.0001; r2= 0.1482, n = 34; (D) Linear plot between fecal score (mean ± SE, n = 34, in arbitrary ranking unit) and fecal bacterial GH5-p4818Cel5_2A abundance (mean ± SE, n = 34, in arbitrary unit) according to a simple linear response model as: y = -0.0416 (± 0.0190) x + 0.7414 (± 0.0562), Pslope= 0.0364; and Pintercept< 0.0001; r2= 0.1298, n = 34. (E) Linear plot between fecal score (mean ± SE, n = 34, in arbitrary ranking unit) and fecal bacterial species Oribacterium sp. (mean ± SE, n = 34, %) according to a simple linear response model as: y = 0.4873 (± 0.2289) x + 0.4697 (± 0.0923), Pslope= 0.0410; and Pintercept< 0.0001; r2= 0.1241, n = 34; (F) Linear plot between fecal score (mean ± SE, n = 34, in arbitrary ranking unit) and fecal bacterial species Lactobacillus salivarius (mean ± SE, n = 34, %) according to a simple linear response model as: y = 0.6834 (± 0.2695) x + 0.5749 (± 0.0469), Pslope= 0.0163; and Pintercept< 0.0001; r2= 0.1673, n = 34; (G) Linear plot between fecal score (mean ± SE, n = 34, in arbitrary ranking unit) and fecal bacterial species Blautia obeum (mean ± SE, n = 34, %) according to a simple linear response model as: y = -1.2961 (± 0.3185) x + 0.8322 (± 0.0555), Pslope= 0.0003; and Pintercept< 0.0001; r2= 0.3409, n = 34; (H) Linear plot between fecal score (mean ± SE, n = 34, in arbitrary ranking unit) and fecal bacterial species p-2534-18B5 sp. (mean ± SE, n = 34, %) according to a simple linear response model as: y = 3.4461 (± 1.3252) x + 0.6030 (± 0.0406), Pslope= 0.0140; and Pintercept< 0.0001; r2= 0.1745, n = 34; (I) Linear plot between fecal score (mean ± SE, n = 34, in arbitrary ranking unit) and fecal bacterial species dgA- 11 sp. (mean ± SE, n = 34, %) according to a simple linear response model as: y = 9.1413 (± 2.1189) x + 0.5568 (± 0.0385), Pslope= 0.0001; and Pintercept< 0.0001; r2= 0.3677, n = 34; (J) Linear plot between fecal score (mean ± SE, n = 34, in arbitrary ranking unit) and fecal bacterial species Mucispirillum sp. (mean ± SE, n = 34, %) according to a simple linear response model as: y = 9.5495 (± 4.0288) x + 0.5973 (± 0.0430), Pslope= 0.0240; and Pintercept< 0.0001; r2= 0.1494, n = 34; (K) Linear plot between fecal score (mean ± SE, n = 34, in arbitrary ranking unit) and fecal bacterial species Streptococcus orisratti (mean ± SE, n = 34, %) according to a simple linear response model as: y = 9.2074 (± 3.5121) x + 0.6047 (± 0.0402), Pslope= 0.0133; and Pintercept< 0.0001; r2= 0.1768, n = 34. The linear response models were visualized and plotted using GraphPad Prism. The linear regression analyses were conducted with the NLIN procedures in SAS. Significance level at P < 0.05 was used for all the parameter estimates. ADG, average daily gain; ADFI, average daily feed intake; and U, mg-min1.

[0136] Detailed Description

[0137] Reference will now be made in detail to embodiments, examples of which are illustrated in the accompanying drawings. In the following detailed description, numerous specific details are set forth in order to provide a sufficient understanding of the subject matter presented herein. But it will be apparent to one of ordinary skill in the art that the subject matter may be practiced without these specific details. Moreover, the particular embodiments described herein are provided by way of example and should not be used to limit the scope of the invention to these particular embodiments. In other instances, well-known data structures, timing protocols, software operations, procedures, and components have not been described in detail so as not to unnecessarily obscure aspects of the embodiments of the invention.

[0138] As used herein, the terms "invention" or "present invention" are non-limiting terms and not intended to refer to any single aspect of the particular invention but encompass all possible aspects as described in the specification and the claims.

[0139] All publications, patent applications, patents, and other references mentioned herein are incorporated by reference in their entirety. The publications and applications discussed herein are provided solely for their disclosure prior to the filing date of the present application. Nothing herein is to be construed as an admission that the present invention is not entitled to antedate such publication by virtue of prior invention. In addition, the materials, methods, and examples are illustrative only and are not intended to be limiting.

[0140] In the case of conflict, the present specification, including definitions, will control. Unless defined otherwise, all technical and scientific terms used herein have the same meaning as is commonly understood by one of skill in the art to which the subject matter herein belongs. It will be further understood that terms, such as those defined in commonly used dictionaries, should be interpreted as having a meaning that is consistent with their meaning in the context of the relevant art and the present disclosure, and will not be interpreted in an idealized or overly formal sense unless expressly so defined herein.

[0141] Reference to “one embodiment,” “an embodiment,” “a preferred embodiment” or any other phrase (e.g. “an aspect”) mentioning the word “embodiment” means that a particular feature, structure, or characteristic described in connection with the embodiment is included in at least one embodiment of the-disclosure and also means that any particular feature, structure, or characteristic described in connection with one embodiment can be included in any embodiment or can be omitted or excluded from any embodiment. The appearances of the phrase “in one embodiment” in various places in the specification are not necessarily all referring to the same embodiment, nor are separate or alternative embodiments mutually exclusive of other embodiments. Moreover, various features are described which may be exhibited by some embodiments and not by others and may be omitted from any embodiment. Furthermore, any particular feature, structure, or characteristic described herein may be optional. Similarly, various requirements are described which may be requirements for some embodiments but not other embodiments. Where appropriate any of the features discussed herein in relation to one aspect or embodiment of the invention may be applied to another aspect or embodiment of the invention. Similarly, where appropriate any of the features discussed herein in relation to one aspect or embodiment of the invention may be optional with respect to and / or omitted from that aspect or embodiment of the invention or any other aspect or embodiment of the invention discussed or disclosed herein.

[0142] It will be understood that any component defined herein as being included in any described embodiment may be explicitly excluded from the claimed invention by way of proviso or negative limitation.

[0143] Definitions

[0144] Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which the invention pertains. Although any methods and materials similar or equivalent to those described herein can be used in the practice for testing of the present invention, the typical materials and methods are described herein. In describing and claiming the present invention, the following terminology will be used.

[0145] It is also to be understood that the terminology used herein is for the purpose of describing particular aspects only, and is not intended to be limiting.

[0146] The articles "a" and "an" are used herein to refer to one or to more than one (i.e., to at least one) of the grammatical object of the article. By way of example, "an element" means one element or more than one element.

[0147] "About" as used herein when referring to a measurable value such as an amount, a temporal duration, and the like, is meant to encompass variations of ± 20% or ± 10%, more typically ± 5%, even more typically ± 1%, and still more typically ± 0.1% from the specified value, as such variations are appropriate to perform the disclosed methods.

[0148] The term “substantially” as used herein denotes that the term or phrase to which this refers is a great or significant extent.

[0149] As used herein the term ‘may’ denotes an option or an effect which is either or not included and / or used and / or implemented and / or occurs, yet the option constitutes at least a part of some embodiments of the invention or consequence thereof, without limiting the scope of the invention.

[0150] The phrase “and / or,” as used herein in the specification and in the claims, should be understood to mean “either or both” of the elements so conjoined, e.g., elements that are conjunctively present in some cases and disjunctively present in other cases. Other elements may optionally be present other than the elements specifically identified by the “and / or” clause, whether related or unrelated to those elements specifically identified unless clearly indicated to the contrary. When the word "or" is used in reference to a list of two or more items, that word covers all of the following interpretations of the word: any of the items in the list, all of the items in the list and any combination of the items in the list.

[0151] As used herein, expressions such as "at least one of," when preceding a list of elements, modify the entire list of elements and do not modify the individual elements of the list.

[0152] “Weanling pig / piglet” (“weaner”) as used herein are piglets taken away from their dam and eat only solid food and water. Piglets are about 3 to about 5 weeks of age. “Weaning” as used herein is introducing infant to an adult diet.

[0153] “Animal” as used herein includes mammals and non-mammals. Animals can include livestock such as but not limited to ruminants such as cattle, sheep, goats, and pigs; non-ruminants such as but not limited to llamas, alpacas and horses; a companionship animal; poultry and fish.

[0154] The term “companion animal” as used herein refers to any animal that is kept as a pet for the company or health benefits of a human. Companion animals can include, but are not limited to, dogs, cats, birds, rabbits, mice, guinea pigs, gerbils, chinchillas, rats, or donkeys.

[0155] “Minimum Viable Product” (MVP) as used herein is a panel of biomarkers used in animal health in animal husbandry used in the management, nutritional, physiological strategies and metagenomics-based breeding and selection strategies for raising healthy animals.

[0156] As used herein, “fecal score” refers to gut health status. Clinical assessment of feces / stool, used to evaluate gut health status, for example aspects of digestion as discussed herein.

[0157] The term “assay” as used herein refers to a procedure that determines the amount of a particular constituent of a mixture or sample. “Assay” can interchangeably be used with the term “test” herein.

[0158] The term “dysbiosis” as used herein refers to an imbalance between the types of organism present in an animal’s natural microflora (gut microbial ecosystem), that may contribute to a range of conditions of ill health.

[0159] As used herein “health performance” refers to body weight gain and voluntary feed intake.

[0160] The term “biomarker” as used herein refers to a substance, such as, but not limited to, a protein, DNA sequence, RNA sequence, or other biological substance or substances that, when detected, indicates a particular healthy or unhealthy state of an animal. The biomarker is an analyte in a sample that is associated with a physiological condition and / or the presence or risk of contracting one or more diseases. The term “healthy” as used herein refers to a state of an animal who is free from detectable disease and is in good health and has a relatively low risk of developing certain diseases. Such an animal is considered “well”.

[0161] The term “sample” as used herein refers to a biological sample from an animal and is in aspects can be liquid such as plasma or semi-solid such as a fecal sample. A sample is easily obtained from an animal. Other samples can be used in the present invention in the same manner described herein, such as, but not limited to blood (from which plasma is isolated), tears, and cerebral spinal fluid (CSF). While plasma or fecal samples are specifically referred to in the description herein, it should be understood that the other types of samples can be interchanged where appropriate and the invention is performed in the same manner. It should be noted that certain biomarkers can be present in one type of sample but not in others and that the biomarker measured can be specific to a plasma sample, a serum sample, etc. A sample can be treated before use for example with a substance that helps to preserve the components being measured from decomposition during storage or shipment, and / or prevents the generation of additional reactive substances outside of the body, and / or retards the growth of microbes in the specimen that might alter the values during storage or shipment. These additive(s) do not themselves alter the values of the tests involved in the panel. However, preferably, the sample is analyzed as soon as possible after collection to reduce the decomposition or further reactions of biomarkers in the panel.

[0162] The term “level” as used herein “refers to the amount, concentration, or activity of a biomarker. The term “level” may also refer to the rate of change of the amount, concentration or activity of a biomarker. A level can be represented, for example, by the amount or synthesis rate of messenger RNA (mRNA) encoded by a gene, the amount or synthesis rate of polypeptide corresponding to a given amino acid sequence encoded by a gene, or the amount or synthesis rate of a biochemical form of a biomarker accumulated in a cell, including, for example, the amount of particular postsynthetic modifications of a biomarker such as a polypeptide, nucleic acid or small molecule. The term can be used to refer to an absolute amount of a biomarker in a sample or to a relative amount of the biomarker, including amount or concentration determined under steady-state or non-steady-state conditions. Level may also refer to an assay signal that correlates with the amount, concentration, activity or rate of change of a biomarker. The level of a biomarker can be determined relative to a control marker or an additional biomarker in a sample.

[0163] A “kit” as referred to herein can include the following assay components: multiwell assay plates / substrates, calibrators for analytes, one or more buffers, diluents, and labels. Reagent components of the kit can be provided as liquid reagents, lyophilized, or combinations thereof, diluted or undiluted, and the kit includes instructions for appropriate preparation and use thereof.

[0164] Ranges: throughout this disclosure, various aspects described herein can be presented in a range format. It should be understood that the description in range format is merely for convenience and brevity and should not be construed as an inflexible limitation on the scope described herein. Accordingly, the description of a range should be considered to have specifically disclosed all the possible subranges as well as individual numerical values within that range. For example, description of a range such as from 1 to 6 should be considered to have specifically disclosed subranges such as from 1 to 3, from 1 to 4, from 1 to 5, from 2 to 4, from 2 to 6, from 3 to 6 etc., as well as individual numbers within that range, for example, 1, 2, 2.7, 3, 4, 5, 5.3, and 6. This applies regardless of the breadth of the range.

[0165] It will be understood that any aspects described as “comprising” certain components may also “consist of’ or “consist essentially of,” wherein “consisting of’ has a closed-ended or restrictive meaning and “consisting essentially of’ means including the components specified but excluding other components except for materials present as impurities, unavoidable materials present as a result of processes used to provide the components, and components added for a purpose other than achieving the technical effect described herein.

[0166] DISCUSSION

[0167] This disclosure relates novel biomarkers and to reliable and rapid and non- invasive biomarker tests to predict / assess growth performance of animals and / or diagnose and / or predict gut health of animals that can help reduce the uses of antimicrobials / antibiotics in both pig and other animal / mammal health management. The animals in one non-limiting embodiment are pigs, in aspects weanling pigs that are susceptible to stress and disease challenge.

[0168] The disclosure describes the new combination of alkaline phosphatase ALP as a metabolomic biomarker, optionally with fecal abundance of endoglucanase gene GH5- p4818Cel5_2A (fGH5) as a metagenomic biomarker for one or more of predicting, identifying, and diagnosing healthy animals. The health may relate to one or more of body weight gain, voluntary feed intake, digestion, feed conversion efficiency, and gut health status (e.g. fecal score). The animal is not limited, and may be a weanling. The animal may be susceptible to stress and disease challenge. The animal may be a pig, the animal may be a weaning piglet.

[0169] Presently, plasma alkaline phosphatase (pALP) activity kinetic parameters may be used as rapid biochemical and metabolomic biomarkers for predicting body weight gain and voluntary feed intake in an animal, such as for example a weanling, in aspects a weanling piglet.

[0170] Further, presently the fecal bacterial multi-functional processive endoglucanase gene GH5-p4818Cel5_2A (fGH5) abundance (relative to the total 16S rRNA gene) is useful as a single metagenomic biomarker for predicting the overall gut health status (fecal score) of an animal, such as for example a weanling, in aspects a weanling piglet.

[0171] Still further, the abundance levels of identified specific fecal bacterial species (relative to the total 16rRNA genes) are useful a biomarker panel for predicting the average daily gain, average feed intake and feed conversion efficiency of weanlings, in aspects weanling piglets. Abundance levels can be determined in a variety of manners such as using a high-resolution and high-accuracy Loop-Genomics-based LoopSeq™ synthetic long-read full-length 16S rRNA gene sequencing platform.

[0172] The panel of individual biomarkers can be designated as the Minimum Viable Product (MVP) for use in animal health in animal husbandry and to develop management, nutritional, physiological strategies and metagenomics-based breeding and selection strategies in order to raise healthy and efficient breeding animals such as pigs and other livestock poultry and aquaculture species.

[0173] Furthermore, the biomarker panel comprising one to several biomarker(s) may be for use for companion animals and may have human application for food and nutrition, health management and pharmaceutical gut health and obesity assessment. The invention provides novel plasma metabolomic and fecal metagenomic biomarkers for animal gut health status and growth performance, such as for pigs inclusive of weaning piglets and thus provides methods for assessing / predicting animal gut health and growth performance. The novel plasma metabolomic and fecal metagenomic biomarkers may be provided in compositions and / or development of kits for use by for example commercial animal production units.

[0174] Herein described gut bacterial communities up to species levels was determined with high-accuracy and high-resolution by using the 16S rRNA gene full-length synthetic long-read sequencing technology provided by the Loop-Seq™ (Callahan et al., 2021). With these metagenomic data, the relationships between the host major phenotypes and gut microbiota at bacterial species level as modulated by therapeutic antimicrobials in weanling pigs were determined.

[0175] A typical combination of antimicrobials was used herein, which included prescribed therapeutic levels of chlortetracycline (aureomycin) and tiamulin as well as pharmacological levels of ZnO, assisting in maintaining weight gain and stimulating appetite during weaning stress or treating bacterial enteritis (scours, bacterial diarrhea) of weanling pigs (CFIA, 2018). The results demonstrate the administration of these therapeutic multi-antimicrobials significantly increased growth performances of weanling pigs; and the growth-promotion effect was positively linked to feed intake, suggesting that therapeutic multi-antimicrobials’ growth-promotion effect is largely driven by enhanced feed intake. On the other hand, the results from efficiency of the digestive utilization of nutrients (i.e., starch, crude fat and dietary fiber) showed that the higher growth rate in antimicrobials group was associated with lower fecal IDF and TDF digestibility coefficient by antimicrobials; meanwhile, the digestive utilization of DM, starch and crude fat did not have any differences in response to antimicrobials administration (Figure 3).

[0176] These data collectively suggest that antimicrobials may promote growth of weanling pigs not through the improvements of efficiency of the digestive utilization of nutrients. Although antimicrobials improved maximal activity Vmax of maltosehydrolytic enzymes (contributing from MGAM and SI) and sucrose-hydrolytic enzyme (contributing from SI) (Figure 4), the present results suggest that in vivo starch is near complete digestion at the end of the distal small intestine, thus not limiting growth rate and feed conversion efficiency of weanling pigs fed corn and SBM-based diets. Additionally, the observed positive associations between the activity of ileal terminal starch hydrolytic enzymes and growth performance suggest that the efficiency and dynamics (e.g., speed and site) of dietary starch digestion may have a positive impact on growth performance.

[0177] These data collectively suggest that antimicrobials may promote growth of weanling pigs through the improvements of efficiency of the post-digestive utilization of nutrients. Antimicrobials improved maximal activity Vmaxof the endogenous AP along the gut longitudinal axis and resulted in enhanced circulating blood AP Vmax(Figures 5 and 6). However, the antimicrobials mediated enhancement in the gut AP F,„„ydid not significantly reduce the cecal digesta and fecal endotoxin activities (Figures 7 and 8). However, blood circulating total endotoxin activity was significantly reduced (Figure 8); and this was likely due to increased blood circulating AP Vmaxas mediated by antimicrobials, suggesting decreased systemic inflammation by the action of the antimicrobials. Furthermore, these data are also consistent with the mRNA abundance responses of the genes involved in control of feed intake, innate immunity and pro- inflammatory responses (Figure 9). Thus, these data suggest that antimicrobials might have promoted growth of the weanling pigs through the improvements of efficiency of the post-digestive utilization of nutrients through down-regulating systemic inflammation.

[0178] These data collectively suggest that antimicrobials may promote growth of weanling pigs through the modulation of gut microbiome. Subsequently, gut bacteria at both cecal digesta and fecal levels were analyzed confirming that antimicrobials exposure decreased gut microbiota diversity in the cecal digesta level. The decrease in gut microbial a-diversity after antimicrobials administration was attributed to the elimination of both pathogenic bacteria and commensal bacteria by the broad-spectrum antibiotics (chlortetracycline) used presently. However, antimicrobials did not change the estimated bacterial density in the cecal digesta and feces. Furthermore, gut bacterial diversity and density did not linked to the growth performances presently. Notably, according to the number of non-redundant ASV shown in the rarefaction curve figures (Figures 10 and 11), gut bacteria in cecal digesta are more responsive to antimicrobials in comparison with fecal samples. Likewise, administration of antimicrobials reduced a- diversity of Chaol index in cecal digesta but had no impact on a-diversity in fecal samples.

[0179] The results herein demonstrate the importance of conducting microbiome response analyses within the gut in order to gain a more accurate understanding of how gut microbiome are impacted by factor under investigation and that presently led to the identification of plasma and fecal biomarkers.

[0180] At weaning, piglets are experiencing dysbiosis due to the various stress, leading to increased susceptibility to post-weaning bacterial diarrhea which is characterized by enrichment of pathogenic bacteria such as Escherichia coli (E. coli), Salmonella spp., and Clostridium perfringens (C. perfringens) but depletion of beneficial bacteria such as Lactobacillus spp. (Fouhse et al., 2016; Gresse et al., 2017; Fan et al., 2023a; Yin et al., 2023). The results herein demonstrate that antimicrobials have no effects on the relative abundance of E. coli, S. suis and Lactobacillus sp. but reduced the relative abundance of other Lactobacillus spp. such as Lactobacillus mucosae, Lactobacillus salivarius and / or Lactobacillus delbrueckii in the cecal digesta and fecal samples compared to the control group. In the meantime, bacterial species of Salmonella enterica and C. perfringens were not detected.

[0181] The most abundant bacterial phyla in the cecal digesta and feces of weanling pigs presently were Firmicutes and Bacteroidetes. The present results further showed that the relative abundance of phylum Bacteroidetes was enriched whereas phylum Firmicutes was decreased by antimicrobials in the cecal digesta; and phylum Proteobacteria was decreased by antimicrobials in both cecal digesta and fecal samples. Phylum Proteobacteria and its lower taxonomic level class Gammaproteobacteria include many potentially pathogenic bacteria such as E. coli and Salmonella spp. (Holman et al., 2014).

[0182] Presently, the antimicrobials-induced decrease in the relative abundance of phylum Proteobacteria was primarily due to reductions in the relative abundance of bacterial species Actinobacillus indolicus and Enterobacter hormaechei as well as Succinivibrio sp. and Desulfovibrio sp. in the cecal digesta and feces, respectively. The former three bacterial species have been reported to be opportunistic pathogens (Chiers et al., 2001; Morton et al., 2015; Yeh et al., 2022). One of the antimicrobials used in this study, tiamulin, has been shown to effective against Actinobacillus pleuropneumoniae (Szancer, 1990). Desulfovibrio species are major sulfate-reducing bacteria in the gut and can release hydrogen sulfide (H2S) through the utilization of dietary sulfate or sulfated mucins.

[0183] Presently, lower abundance of Desulfovibrio sp. were found to be associated with higher feed intake. It is conceivable that the reduced H2S, attributed to lower Desulfovibrio sp. abundance, could contribute to the higher feed intake and thus growth promotion as induced by antimicrobials. Other zoonotic or opportunistic bacterial pathogens declined or eliminated in relative abundance in response to antimicrobials included Solobacterium sp. (Alauzet et al., 2021), Campylobacter spp. {Campylobacter lanienae and Campylobacter colt) (WHO, 2020), Bacillus cereus (Enosi Tuipulotu et al., 2020) and Rothia nasimurium (Wang et al., 2021a) in cecal digesta as well as Campylobacter spp. {Campylobacter sp. and Campylobacter lanienae) and Corynebacterium sp. (Hacker et al., 2016) and Enterococcus villorum (Vancanneyt et al., 2001) in the fecal samples. Presently, the depletion of Campylobacter coli in cecal digesta was associated with increased growth and growth rate. Collectively, the present data support that antimicrobials may maintain the health and growth of weanling pigs through, at least partially, the mitigation of zoonotic or opportunistic bacterial pathogens.

[0184] However, antimicrobials could also favor the growth of pathogens or harmful bacteria. For example, relative abundances of bacterial species Pasteurella sp. in the cecal digesta and Parasutterella sp. in cecal digesta and feces, which belong to phylum Proteobacteria and class Gammaproteobacteria, were enriched in the antimicrobials group. Many Pasteurella species are zoonotic pathogens and can cause life-threatening pneumonia in animals and human (Wilson and Ho, 2013). Enrichment of Parasutterella sp. has been associated with inflammatory bowel disease (IBD), obesity and diabetes (Chen et al., 2018; Ju et al., 2019; Henneke et al., 2022). Herein was identified associations of high fecal Parasutterella sp. abundance with the improvements of feed intake and growth, suggesting that Parasutterella sp. serve as a biomarker for the prediction of feed intake and growth in weanling pigs or of obesity in humans.

[0185] Presently, enrichments of bacterial species Roseburia sp., Oribacterium sp., and Rikenellaceae sp. as well as reductions of bacterial species Succinivibrio sp. and Veillonella parvula in the cecal digesta, as induced by antimicrobials, were found to be associated with increased feed intake and thus growth improvement. Both Roseburia sp. and Oribacterium sp. are genus of Lachnospiraceae family. Roseburia species are known to be the major SCFAs producers and can prevent gut inflammation through their antiinflammatory effects (Kellermayer, 2019). Their association with increased BW has also been reported (Gardiner et al., 2020). The role of Oribacterium sp. is unclear. Rikenellaceae species, hydrogen (H2)-producing bacteria, have been shown to attenuate IBD by selectively neutralizing cytotoxic reactive oxygen species (Zhang et al., 2020). In addition to the modulation of gut inflammatory and oxidative status, comparing microbiome compositions between high and low efficiency in pigs found that pigs with higher abundance of Roseburia spp. and / or Rikenellaceae spp. were associated with higher feed efficiency as shown with the present results. Succinivibrio sp. and Veillonella parvula can produce succinate by fermenting glucose and other carbohydrates (Santos and Thompson, 2014; Angelakis et al., 2015). The present findings suggest that antimicrobials could favor the growth of anti-inflammatory gut bacteria species but limit the growth of pro-inflammatory gut bacteria species, through which the gut inflammatory tone was decreased and consequently feed intake and thus growth as well as feed efficiency was improved in weanling pigs.

[0186] Of the fecal bacterial species that were selected as non-invasive biomarkers for growth performance, little is currently known about the bacterial species p-1088-a5 sp. and Defluviitaleaceae sp. Defluviitaleaceae sp. belongs to order Clostridiales. A higher abundance of Clostridiales has been consistently observed in high-fat-diet-induced obese mice (Li et al., 2019; Liang et al., 2021a). It was presently observed that enrichment of Defluviitaleaceae sp. was linearly associated with increased feed intake, as regulated by antimicrobials, which may provide some insights into Clostridiales’s role in increasing weight gain or promoting growth. In terms of feed efficiency, lower abundance of Selenomonas sp., Mitsuokella sp., Lachnoclostridium sp., and Streptococcus orisratti, as mediated by antimicrobials, were linearly associated with lower F:G (higher feed efficiency). Although the roles of Selenomonas sp. and Mitsuokella sp. remain largely unknown, their higher taxonomic level Veillonellaceae family is regarded as a pro- inflammatory family of bacteria as consistent enrichments of this family were seen in patients with chronic gut diseases such as IBD and irritable bowel syndrome (IBS) (Bonder et al., 2016) as well as in obese people with obesity-related inflammation (Aranaz et al., 2021). Bacterial species Lachnoclostridium sp. that belong to Lachnoclostridium genus can ferment some mono- and disaccharides to produce acerate as the major SCFAs products (Yutin and Galperin, 2013). Enrichment of Lachnoclostridium at genus or species level has been a significant feature for chronic gut inflammation (Zhang et al., 2019; Davrandi et al., 2022), obesity (Zhao et al., 2017; Valido et al., 2022), and colorectal adenoma and cancer (Liang et al., 2020 & 2021). Therefore, it is conceivable that decreases in the abundance of these inflammation-facilitated may might contribute to the improvements of feed efficiency as less fuels are spared for inflammation. Bacteria genera of Lachnoclostridium as well as Selenomonas and Mitsuokella, respectively, were found less abundant in more-feed-efficient pigs. Unlike Streptococcus suis (S. suis) -known as an important zoonotic pathogen for both swine and human), the role of Streptococcus orisratti remains to be defined. Streptococcus was generally less abundant in more feed-efficient pigs which may be due to the pathogenic nature of Streptococcus.

[0187] In summary, the present evidence herein indicates that the growth-promoting effects of therapeutic multi-antimicrobials in weanling pigs are primarily attributed to the stimulation of feed intake, rather than improvements in the efficiency of nutrient digestion (i.e., starch, crude fat, and dietary fiber). The application of therapeutic multiantimicrobials not only helps to control numerous zoonotic and opportunistic bacterial pathogens, such as Campylobacter spp. - which is one of the leading causes of diarrhea in humans worldwide - but also supports the growth of anti-inflammatory bacterial species such as SCFA-producing bacterial species in weanling pigs. These alternations in gut microbiome as modulated by therapeutic multi-antimicrobials collectively contributes to the improvements of growth performance in weanling pigs. This also provides the identification of fecal bacterial species that can be used to predict gut health status.

[0188] The impacts of antimicrobials prescription on gut and blood circulating total alkaline phosphatase maximal enzyme activity and endotoxin activity, gut alkaline phosphatase and other host target intestinal gene expression in terms of mRNA abundances as well as the gut health endpoint of fecal score and cecal digesta and fecal endotoxin activity are now determined and described herein..

[0189] The therapeutic antimicrobials changes of the gut microbiota density, diversity and compositions up to the bacterial species level was determined using the Loop-Seq™ based high-resolution and high-accuracy synthetic full-length 16S-RNA gene sequencing platform.

[0190] Relationships between the growth performances, gut health and nutrient digestive utilization endpoints and the host physiological factor (i.e., alkaline phosphatases), gut microbiome at bacterial species level and a specific bacterial marker gene (i.e., GH5- p4818Cel5_2A) were determined leading to the present identification of physiological factors, and the specific bacterial multi-functional processive endocellulase marker gene and fecal bacterial species that serve as effective metabolic and metagenomic biomarkers for predicting growth performances and gut health in weanling pigs.

[0191] The disclosure will be further illustrated by the following, non-limiting Examples.

[0192] EXAMPLES

[0193] The invention is further described in detail by reference to the following experimental examples. These examples are provided for purposes of illustration only, and are not intended to be limiting unless otherwise specified. Thus, the invention should in no way be construed as being limited to the following examples, but rather, should be construed to encompass any and all variations which become evident as a result of the teaching provided herein.

[0194] Without further description, it is believed that one of ordinary skill in the art can, using the preceding description and the following illustrative examples, make and utilize the described invention herein and practice the claimed methods. The following working examples therefore, specifically point out the typical aspects of the present invention.

[0195] SUMMARY OF FINDINGS

[0196] A combination of antimicrobials was employed, including chlortetracycline, tiamulin and zinc oxide at 220, 31.2 and 2358 mg / kg, respectively, to the diets of weanling pigs for 3 weeks. The growth-promoting effects of the therapeutic antimicrobials were associated with increased feed intake; improved feed to gain ratio but reduced digestive utilization of dietary fiber and the unaffected digestive utilization of dietary starch and crude fat, indicating the post-digestive route of effects. Therapeutic antimicrobials reduced or eliminated the relative abundances of the bacterial pathogens such as Streptococcus spp. and the zoonotic Campylobacter spp. as well as substantially decreased the relative abundances of Lactobacillus spp. in the cecal digesta and feces. Fecal relative abundances of p-1088-a5 sp., Parasutterella sp., Defluviitaleaceae sp., Parasutterella sp.; Selenomonas sp., Mitsuokella sp., Lachnoclostridium sp. and Streptococcus orisratti may serve as non-invasive biomarkers for the prediction of porcine growth performances.

[0197] Therapeutic antimicrobials up-regulated the AP (alkaline phosphatase)- Vmaxalong the small-large intestinal longitudinal axis and in the circulating blood plasma (Figures 5 and 6). Plasma AP-I4„ymay thus serve as a novel blood metabolomic biomarker for predicting porcine growth performances.

[0198] Fecal relative abundances of the GH5-p4818Cel5_2A endocellulase gene as well as Blautia obeum, Oribacterium sp., Lactobacillus salivarius, p-2534-18B5 sp., dgA-11 sp., Mucispirillum sp. and Streptococcus orisratti may serve as biomarkers for predicting porcine gut health. Therapeutic antimicrobials down-regulated the blood total endotoxin activity and permeability and inflammation-related gene mRNA abundances in the hindgut, which were associated with the growth performance and gut health endpoints and abundances of the identified specific cecal-fecal bacterial species in the weanling pigs.

[0199] Materials and Methods

[0200] Procedures in the animal utilization protocol (AUP of #3370) for the care and treatment of the weanling pigs were reviewed and approved by the Animal Care Committee at University of Guelph in accordance with the guidelines established by the Canadian Council of Animal Care (CCAC, 1993).

[0201] Animals, diets, and experimental design

[0202] A total of 170 crossbred barrows (Duroc x Landrace x Yorkshire) were randomly selected from different sows, on d 19-21 with an average initial body weight (BW) of 6.9 ± 0.1 kg and were used in this study. Both experimental phase-II weanling pig (7-11 kg BW) diets, i.e., Control vs. Antimicrobial diets, were corn, soybean meal (SBM) and dried whey-based and were formulated to meet or exceed the NRC (2012) nutrient requirements. The antimicrobial diet was supplemented with prescribed therapeutic multiple antimicrobials of aureomycin 220, tiamulin 31.2 and ZnO 2,358 at mg / kg diet. Both diets were also added the titanium at 0.30% as the digestibility marker and then mixed, pelleted and crumbled. The weanling pigs were assigned to the two experimental diets for 21 d according to a randomized complete block design with floor pens not being washed during the study to mimic practical sanitary condition (Hayhoe et al., 2022).

[0203] Growth performance and fecal score measurements, sample collection and processing

[0204] Piglets were weighed out upon their arrival day then weekly, daily feed allowance was recorded daily on a per pen basis; and waste feed were recovered for each pen and were deducted from their feed allowance after drying in the oven at 65°C (Hayhoe et al., 2022). Fecal score was measured according to the method described in Yin (2021). Briefly, fresh feces found around the identified toilet area were scored (0 - 3 scale points) twice a day on a pen basis according to the followings: 0 = no distress with normal shape and color feces; 1 = mild distress with a sign that runny feces occurred 1- 2 times daily; 2 = moderate distress with signs that runny feces occurred frequently in the day; and 3 = severe distress with signs that bloody runny feces occurred in the day.

[0205] The two diet samples were collected at the beginning of each experimental block period. On d 15, fecal samples were daily collected and pooled within each pen, and were immediately stored at -20 °C after collection. All of the frozen fecal samples collected during the last week of the trial were further freeze-dried, finely ground and sealed in air-tight bags to be stored in a cold storage room for further analyses (Hayhoe et al., 2022). On d 22 of the experiment, blood samples were collected from orbital sinus and were centrifuged at 2,500 x g at 4 °C for 15 min to recover plasma, which was then aliquoted and immediately stored at -80 °C; and immediately after piglets were anesthetized and euthanized, the small and large intestines were removed, segmented, sampled and sample being processed by following our previous procedures (Lackeyram et al., 2010; Hayhoe et al., 2022; Yin et al, 2023).

[0206] Nutritional, chemical and biochemical analyses Dry matter (DM) content in diet, ileal and cecal digesta as well as fecal samples was analyzed according to the AOAC method (2007). Total titanium oxide (TiO2) content in diet, ileal and cecal digesta as well as fecal samples was measured by adapting the procedures by Myers et al. (2004). Resulting sample absorbance was measured at 410 nm using the BioTek Synergy Hl plate reader. Starch content in diet, ileal and cecal digesta as well as fecal samples was determined enzymatically with a commercial assay kit (Rideout et al., 2008). Crude fat (CF) content in diet and fecal samples was analyzed by using the ANKOMX";' Extraction System with petroleum ether as extraction solvent (Thiex et al., 2003). The insoluble dietary fibre (IDF), soluble dietary fibre (SDF) and total dietary fibre (TDF) contents in diet and fecal samples were measured by using an enzymatic-gravimetric method with a commercial assay kit (Huang and Ma, 2016). Total volatile sulfide compounds as the hydrogen sulfide unit in the plasma samples were determined by the methylene blue method (Moest, 1975). Indole and indole analogs contents in the plasma samples were determined using the hydroxylamine indole assay (HIA method) and Kovacs assay (Kovacs method), respectively, according to Darkoh et al. (2015).

[0207] Endotoxin, i.e., LPS activities, expressed as endotoxin activity unit (EU), in blood plasma, cecal digesta digesta and fecal samples were determined by following the Limulus amebocyte lysate (LAL) assay principles (Kaliannan et al., 2013). Freshly thawed cecal digesta (0.400 g) and freeze-dried and homogenized fecal (0.050 g) samples were weighted out and suspended in 5 mL endotoxin-free water and were further diluted to 1,350,000 to 13,500,000-fold prior to the spectrometry. Blood plasma samples were heated at 70 °C for 10 min and incubated in ultrasonic bath at 37 °C for 10 min to enhance LPS exposure. The pre-treated plasma samples were diluted for 180 - 360 times. The diluted samples were assayed with the ToxinSensorTM chromogenic LAL endotoxin kit by using the E. coli endotoxin standard (0 - 0.25 EU) (GenScript, Piscataway, NJ).

[0208] Both MGAM and SI activities were analyzed according to the principles of Dahlqvist (1964). Both enzyme kinetics were conducted with the jejunal and ileal tissue homogenates as well as 0-60 mM and maltose 0-250 mM sucrose at pH 6.0 by following our previous procedures (Fan et al., 2002; Lackeyram, 2012). The total alkaline phosphatase (AP) maximal activity ( Vmax) in the gut tissue homogenates and plasma were analyzed based on our previous procedures (Lackeyram et al., 2010) with modifications of the incubation temperature at 40 °C; incubation media pH at 6.5 and 7.3 for gut tissue homogenates and plasma, respectively, and the substrate incubation media concentration at 15 mM of p-nitrophenyl phosphate, reflecting the variable porcine AP isoforms’ Kmvalues (Yin et al, 2023).

[0209] Target terminal starch digestive enzyme protein sequence alignments

[0210] The immunogen used to generate the anti-human maltase-glucoamylase (MGAM) polyclonal antibody (corresponding to the human MGAM amino acid residues 213-392, NCBI accession no. NP_004659.2,) was aligned with the porcine MGAM (NCBI accession no. XP_020934755.1,) and sucrase-isomaltase (SI) (NCBI accession no. XP_020925407.1), respectively, by using the Clustal Omega multiple sequence alignment program (https: / / www.ebi.ac.uk / Tools / msa / clustalo / ). The alignment results were then visualized by using ESPript 3.0 (http: / / espript.ibcp.fr / ESPript / ESPript / ). In addition, protein sequences of the MGAM between human (NCBI accession no. NP_004659.2) and porcine (NCBI accession no. XP_020934755.1) as well as protein sequences of SI between human (NCBI accession no. NP_001032.2) and porcine (NCBI accession no. XP_020925407.1) were aligned and visualized by using the above-mentioned website services.

[0211] Western blotting analyses of the target enzyme proteins

[0212] The protein abundance analyses of MGAM and SI in the gut tissues by the Western blotting were performed according to previously established procedures (Lackeyram et al., 2010). The partial porcine MGAM sequence (corresponding to porcine MGAM amino acid 180-359, NCBI accession no. XP_020934755.1) and the SI sequence (corresponding to porcine SI amino acid 188-367, NCBI accession no. XP_020925407.1) were demonstrated to have 88 and 66% respective homology with the human anti-MGAM polyclonal antibody immunogen (corresponding to human MGAM amino acid 213-392, NCBI accession no. NP_004659.2) based on Clustal Omega multiple sequence alignment program (https: / / www.ebi.ac.uk / Tools / msa / clustalo / ). Therefore, the protein abundance analyses for both MGAM and SI were performed using the same primary rabbit anti-human MGAM polyclonal antibody (Abeam, Cambridge, UK). The membrane blots were imaged by using the Bio-Rad system (Yin et al, 2023). The abundance of p-actin was used to normalize the abundance of the target proteins (Lackeyram et al., 2010).

[0213] Primers design for the target enzyme genes

[0214] Primers for amplification of the target enzyme genes were developed using NCBI online server (https: / / www.ncbi.nlm.nih.gov / gene / ) and were designed to span an exon-exon junction. Primers were designed based on porcine MGAM (NCBI accession no. XM_021079096.1) and SI (NCBI accession no. XM_021069748.1) sequences. Primer sequences for MGAM and SI are as follows: (1) MGAM forward primer, 5’- ACACCTACTTCAGCCGTCAG-3’; and reverse primer, 5’- ATGCTTTGCCCATCATCCCA-3’; and (2) SI forward primer, 5’- ACTACAACTGCCAGCCGAAA-3’; and reverse primer 5’- ACCGCGTCTATCAACCCAAG-3’. Primer sequences for p-actin were obtained from Yin (2021) with forward primer, 5’- CTGCGGCATCCACGAAACT -3’; and reverse primer, 5’- AGGGCCGTGATCTCCTTCTG -3’. Primer sequences for other appetite, gut permeability and inflammation related target genes are summarized in Table 1.

[0215] RNA extraction and real-time RT-PCR analyses

[0216] The mRNA abundances analyses of the MGAM and SI genes were performed according to our previous procedures (Fan, 2023) using the Trizol reagent (Invitrogen, Carlsbad, CA) and PureLink™ RNA Mini Kit (Thermo Fisher Scientific, Rockford, IL). The real-time quantitative RT-PCR (qRT-PCR) was performed in a StepOnePlus™ Real- Time PCR System (Thermo Fisher Scientific, Rockford, IL) using a SYBR® Green Master Mix kit (Bio-Rad, Hercules, CA). The relative mRNA abundances of the target MGAM and SI genes were normalized to the data of the control diet-fed piglets using the 2-MCtmethod (Yang et al., 2011).

[0217] Extracting and quantifying microbial metagenomic DNA in cecal digesta and fecal samples

[0218] DNA extraction procedures were performed according to our previous procedures (Fan, 2023) by using the QIAamp PowerFecal Pro DNA kit (QIAGEN, Hilden, Germany). The extracted and quantified metagenomic DNA samples were further diluted to 5 ng / pL for sequencing library preparation and the synthetic full- length 16S rRNA gene sequencing with the LoopSeq™.

[0219] Estimating total porcine bacteria density in cecal digesta and fecal samples

[0220] Total porcine bacteria density in cecal digesta and fecal samples were estimated according to our previous method (Fan, 2023). Briefly, the microbial DNA quantification-based method (Contijoch et al., 2019) as well as the estimated human stool bacterial average genome size (3.9 Mb, mega base pairs) (Nayfach and Pollard, 2015) and the estimated genomic DNA weight (1 pg DNA = 978 Mb) (Dolezel et al., 2003) were used for estimating total porcine bacterial load in terms of density and total bacterial output in cecal digesta and fecal samples.

[0221] Determination of bacterial gene GH5-p4818Cel5 2A abundance

[0222] The bacterial processive endocellulase gene GH5-p4818Cel5_2A relative abundances in the isolated metagenomic DNA samples (5 ng / pL) were determined by the quantitative PCR (qPCR) analyses as described above. The bacterial gene GH5- p4818Cel5_2A was previously reported by Wang et al. (2021). Primers for GH5- p4818Cel5_2A (NCBI GenBank#: MH373350.1) were designed using Primer 3 (http: / / frodo.wi.mit.edu / primer3 / primer3_code.html) as follows: forward primer, 5’- TGCACAGGCGATGGTAACA-3’; and reverse primer, 5’- TGCCAGTCTACAATTACGTACATTCC-3’. Primers for 16S rRNA (forward primer, 5’- ACTCCTACGGGAGGCAGCAGT-3’; and reverse primer, 5’- TATTACCGCGGCTGCTGGC-3’). All sample runs were conducted in duplicate. The relative abundances of the target gene GH5-p4818Cel5_2A in the samples were normalized to the data of the control diet-fed piglets by using the 2-AACtmethod with the 16S rRNA gene for the housekeeping (Yang et al., 2011).

[0223] Sequencing library preparation and the full-length 16S rRNA gene sequencing

[0224] The above extracted and quantified porcine cecal digesta and fecal metagenomic DNA samples (at 5 ng / pL) were further prepared for sequencing libraries with the commercial LoopSeq™ 16S Long-read kits (Callahan et al., 2021). For each LoopSeq 16S rRNA gene synthetic long-read kit, up to 24 samples were processed simultaneously and captured ~12,000 amplicon DNA molecules per sample (~300,000 amplicon DNA molecules from a complete kit run) with an Illumina sequencing platform run in 150-bp paired-end (PE) mode (Callahan et al., 2021). In this study, a total of 68 metagenomic samples, which were prepared from equal number of cecal digesta and fecal samples, were sequenced, yielding over 50 Gb of data.

[0225] Raw short-reads, generated by using the LoopSeq™ 16S Long Read kits with an Illumina sequencing platform run in PEI 50 mode, were processed into assembled synthetic long-read (SLR) contigs by using cloud-based platform bioinformatic pipeline (Callahan et al., 2021). The assembled LoopSeq SLR contigs generated by the above bioinformatic processing were further subjected to quality filtration, denoising and chimera removal with the denoised amplicon sequence variants (ASVs) inferred by the DADA2 algorithm (Callahan et al., 2021).

[0226] Alpha-diversity endpoints of Simpson index, Shannon index and Chao-1 index, beta-diversity endpoint of the principal component analysis (PCA), as well as rarefaction curves and the extrapolated rarefaction curve plateau values of Bootstrapping, Chao and Jackknife estimators were further analyzed by using the denoised ASVs and the phyloseq R package (McMurdie and Holmes, 2013) and / or by using RStudio (RStudio Desktop, version 2021.09.2, RStudio, Boston, MA). Here we consolidated full-length ASVs to represent their full-length 16S rRNA genes in all of our porcine metagenomic DNA samples. Each of the full-length 16S rRNA genes of the metagenomic DNA samples was blasted to NCBI database for matching and identifying their strain-level taxonomies at 100% nucleotide identity.

[0227] Calculations and statistical analyses

[0228] The apparent ileal, cecal and total tract digestibility values of DM, IDF, SDF, TDF, starch and CF in the diets were calculated by the digestibility marker technique (Fan et al., 2001). The outputs of total bacteria in the porcine cecal digesta and fecal samples fed the experimental diets were calculated according to the marker dilution technique (Fan and Sauer, 1997). The maltose- and sucrose-hydrolytic activity kinetics for the jejunal and ileal tissue homogenate were fitted and plotted according to the Michaelis- Menten model using GraphPad Prism (v9.0.0, GraphPad Software, San Diego, CA). Significance (P < 0.05) of all the kinetic parameter estimates was examined by the pooled two-tailed Student’s t-test.

[0229] Data were analyzed using PROC GLIMMIX of SAS (OnDemand, SAS Institute Inc., Cary, NC) with dietary treatment as fixed effect and experimental period as random effect. Homogeneity of variances was examined and confirmed first by the Shapiro-Wilk test (P < 0.05) for all endpoints (Razali and Wah, 2011). When the residuals had a normal distribution, analysis of variance (ANOVA) was used for comparisons between the two treatment groups. When the residuals had an abnormal distribution, data were log transformed to address the heteroscedasticity, back-transformed least square means (BTLSMEANS) and back-transformed standard errors (BTSE) for the mean (BTLSMEANS ± BTSE) for the relevant endpoints were tested. Non-normally distributed residuals or a nonparametric Kruskal-Wallis test was performed if log transformation did not change the distribution of variances (Bergamaschi et al., 2020; Gu et al., 2021; Nakatsuji et al., 2021).

[0230] Least square means (LSMEANS) tests (for the endpoints with unequal number of observations) were carried out for fixed effect for all endpoints. The Shapiro-Wilk Test, Kruskal-Wallis nonparametric test, the LSMEANS tests, and the BTLSMEANS tests, and the Spearman correlations between various endpoints were all conducted by using the SAS.

[0231] Comparisons of the bacterial density and output between cecal digesta and fecal samples were conducted by using an independent sample t-test procedure of SAS. Comparisons of the extrapolated rarefaction non-redundant denoised ASV values of Bootstrapping, Chao, and Jackknife estimators were conducted by using the unpaired pooled t-tests in GraphPad Prism. Comparisons of the alpha-diversity endpoints, including Simpson index, Shannon index and Chao-1 index, and the bacterial relative abundances at different levels (phylum to species) between cecal digesta and fecal samples were conducted by using PROC GLIMMIX procedure of SAS.

[0232] The linear response models were visualized and plotted using GraphPad Prism. The linear regression analyses were conducted with the PROC NLIN procedures of SAS. Significance level at P < 0.05 was used for all the regression parameter estimates. Data are presented as parameter estimates, means or LSMEANS ± (SE); or BTLSMEANS ± BTSE or pooled standard errors of the means (SEM). Rvalues < 0.05 were considered significant.

[0233] RESULTS / DISCUSSION

[0234] Therapeutic multi-antimicrobials improved growth performances

[0235] Dietary administration of antimicrobials significantly increased the overall 3-wk growth performance endpoints, including the final BW (Control, 13.72 ± 0.24 vs. Antimicrobials, 14.75 ± 0.24 kg-, P < 0.0001), ADG (Control, 0.301 ± 0.009 vs. Antimicrobials, 0.348 ± 0.009 kg / d, P < 0.0001), ADFI (Control, 0.414 ± 0.012 vs. Antimicrobials, 0.451 ± 0.013 kg / d, P = 0.0021) and F: G ratio (Control, 1.383 ± 0.022 vs. Antimicrobials, 1.300 ± 0.023 kg / kg-, P = 0.0050) in comparison with the nonantimicrobial control diet (Figure 1). The Spearman’s correlations revealed that the ADG was positively (P < 0.001) associated with the ADFI and F:G ratio [Figure 14(A)- 15(C)],

[0236] Table 1: Primers used for the RT-PCR amplification analyses other appetite, gut permeability and inflammation related target genes. Therapeutic multi-antimicrobials improved gut health via increased cecal total alkaline phosphatase (AP) maximal activity K„„, and the hindgut bacterial cellulase gene abundance

[0237] Fecal score, reflecting the overall cumulative incidence of diarrhea, was used as an indicator of gut health as reported in the literature (Liu et al., 2008; Conway etal., 2022). As shown in Figure 2(A), piglets administered with antimicrobials had a lower (P < 0.05) fecal score than the control group, suggesting that dietary administration of the combined antimicrobials had significantly improved the gut health of the weanling pigs. However, piglets administered with antimicrobials did not show higher (P > 0.05) cecal and fecal LPS endotoxin activities than these of the control group, suggesting that dietary administration of the combined therapeutic antimicrobials did not mediate the gut health of the weanling pigs via modulation of the gut luminal endotoxin activities (Figure 7). Spearman’s correlation analyses revealed that the antimicrobials-associated improvements on growth rate and feed conversion efficiency were associated (P < 0.05) with the better gut health (i.e., lower fecal score) (data not shown), the latter of which was subsequently found to be linked (P < 0.05) to the higher cecal total AP- Vmaxas modulated by the antimicrobials (Figure 17).

[0238] GH5-p4818Cel5_2A is a bacterial mult-functional processive endocellulase. In this study, the relative abundance of the GH5-p4818Cel5_2A gene in the cecal digesta and feces was observed and found dramatically higher (P < 0.05) in the piglets of the antimicrobial administration group [Figure (2B)]. Spearman’s correlation and linear regression analyses further revealed the associations and linear regression relationships of the higher bacterial GH5-p4818Cel5_2A gene abundances in the cecal digesta and feces with better gut health as modulated by the antimicrobials [Table 8; Figure 25(C) and 25(D)], which suggest that the abundance of bacterial GH5-p4818Cel5_2A gene may be used as a novel microbiome metagenomic biomarker in predicting porcine gut health.

[0239] Therapeutic multi-antimicrobials modulated gut and blood plasma circulating AP maximal enzyme activity I / „„,, and gut AP gene expression linking to growth performance improvements Dietary administration of antimicrobials increased (P < 0.05) the total AP-I / ,„„yin the proximal jejunum, distal ileum, cecum and blood plasma but did not affect (P > 0.05) the total AP- Vmaxin the colon [Figure 5(A) - (F)]. The total AP-I / ,„„yin the plasma and colon was higher than that in jejunum, ileum and cecum [Figure 5(A) - (B)]. The Spearman’s correlation revealed that blood plasma total AP-I / ,„„ywas positively associated with (P < 0.05) the jejunal total AP Vmax(data not provided here!), suggesting that AP originating from the jejunum might have entered the bloodstream and contribute to the plasma total AP-I / ,„„y. However, regression analyses using simple linear, quadratic and exponential model indicated that no linear and non-linear relationships were found between the plasma and the jejunal total AP- Vmax(data not shown here!). Furthermore, higher plasma total AP- Vmanas induced by antimicrobials, was found to be linked to improvements of feed intake and growth rate (P < 0.05) (Figure 17). Regression analyses further confirmed their simple linear relationships (P < 0.05) [Table 4; Figure 25(A) -25 (B)], which support the potential role of the plasma total AP-I / ,„„, as a novel metabolic biomarker for the prediction of porcine growth performances.

[0240] The mRNA abundance of IAP was upregulated (P < 0.05) in the proximal jejunum but was downregulated (P < 0.05) in the cecum by antimicrobials [Figure 5(G) - (I)]. No differences (P > 0.05) were observed in the distal ileum and colon between the two treatment groups [Figure 5(H) - (J)]. The mRNA abundance of TNAP was decreased (P < 0.05) in the distal ileum and cecum in the antimicrobials-administered group [Figure 5(H) - (I)] , whereas no differences (P > 0.05) were observed in the proximal jejunum and colon between the two groups [Figure 5(G) - (J)] . In the antimicrobials- administered group, the relative mRNA abundance of both IAP and TNAP were higher (P < 0.05) in the jejunum compared to that in the ileum, cecum and / or colon [Figure 18A-C], The Spearman’s correlations analyses identified specific cecal and the fecal bacterial species that were positively associated with the blood plasma AP-I / ,„„yas well as the gut AP- Vmaxalong the small and the large intestinal longitudinal axis in the weanling pigs [Figure 16(A) - (CE)], suggesting that the gut endogenous AP contributed to the maintaining of gut microbiome along the entire small and the large intestinal longitudinal axis, as modulated by the administration of antimicrobials. Therapeutic multi-antimicrobials decreased the apparent fecal digestibility of IDF and TDF

[0241] Dietary administration of the antimicrobials did not affect (P > 0.05) the apparent digestibility of DM at the ileal, cecal, fecal and hindgut levels in comparison with the control group [Figure 3(A) - (D)]. The antimicrobials had a tendency (P = 0.0957) of reducing the apparent fecal crude fat (CF) digestibility [Figure 3(1)]. Furthermore, antimicrobials administration did not affect (P > 0.05) the apparent fecal digestibility of SDF [Figure 3(J)]. However, the antimicrobials decreased by the apparent fecal digestibility of IDF (P = 0.0143) and TDF (P = 0.0143) compared to the control group [Figure 3(K) - (L)]. The Spearman’s correlations analyses revealed that growth rate (i.e., ADG) and voluntary feed intake were negatively associated with (P < 0.05) the apparent fecal digestibility of IDF and TDF as altered by antimicrobials [Figure 14(C)], The Spearman’s correlations analyses shown that Fecal DM, starch, and crude fat digestibility were positively associated (P < 0.05) with fecal IDF and TDF digestibility [Figure 15(A), (B), (E) and (F)]. The Spearman’s correlations analyses identified special bacterial species that were associated with the digestibility of DM, fibre, and CF digestibility at the cecal and the fecal levels [Figure 16(A) - (F)]. Furthermore, the Spearman’s correlations analyses identified specific bacterial species that were positively associated with the growth performance endpoints of ADG, ADFI and F:G ratio at the cecal and the fecal levels [Figure 16(A) and (E)]. Regression analyses further confirmed their simple and / or multiple linear relationships (P < 0.05) [Table 5 - 7; Figure 24(A) - (H)], which support the potential role of the identified specific bacterial species as the potential fecal metagenomic biomarkers for the prediction of the main porcine growth performance endpoints.

[0242] Therapeutic multi-antimicrobials did not affect starch digestibility and the gut terminal starch digestion enzyme affinity and their gene expression but increased the activities of the porcine distal small intestinal terminal starch digestive enzymes MGAM and SI.

[0243] Dietary administration of the antimicrobials did not affect (P > 0.05) the apparent digestibility of total starch at the ileal, cecal, fecal and hindgut levels in comparison with the control group [Figure 3(E) - (H)]. In this study, dietary administration of the therapeutic multi-antimicrobials did not enhance (P > 0.05) the affinity Kmand Vmaxof maltose-hydrolytic enzymes (MGAM-SI) and sucrose-hydrolytic enzyme (SI) in the jejunal tissue homogenates; and affinity of the MGAM-SI and SI in the ileal tissue homogenates; however, Vmaxvalues of MGAM-SI and SI were improved (P < 0.05) in the ileal tissue homogenates by the dietary multi-antimicrobials in comparison with the control group (Table 1). No significant differences were observed (P > 0.05) for the jejunal and ileal protein abundances (relative to p-actin) of MGAM and SI [Figure 4(A) - (B)], and for the jejunal and ileal mRNA abundances (relative to p-actin) of MGAM and SI in weanling pigs administrated with the therapeutic antimicrobials in comparison with the control group [Figure 4(C) - (D)]. The Spearman’s correlations analyses identified special bacterial species that were associated with the digestibility of starch as well as the terminal starch digestive enzyme biochemical and molecular end-points at the cecal and the fecal levels [Figure 16(C), (D), (G) and (H)].

[0244] Therapeutic multi-antimicrobials down-regulated the transcriptional expression of the gut permeability and inflammation related genes in contributing to the improved gut health and growth performances in association with specific bacterial species

[0245] Although the therapeutic multi-antimicrobials did not affect (P > 0.05) the cecal digesta and the fecal LPS endotoxin activities (Figure 7), they (P < 0.05) decreased the circulating blood plasma fLPS endotoxin activity (Figure 8). As shown in Figure 9(A) - (N), the antimicrobials down-regulated (P < 0.05) the target pathway gene expression in terms of their mRNA abundances primarily in the cecum and the colon in the weanling pigs. The Spearman’s correlations analyses shown that more of the target pathway gene mRNA abundance responses in the colon and cecum rather than the jejunum and the ileum were positively associated (P < 0.05) with the weanling porcine growth performances [Figure 19(A), (B), (C) and (D)]. Similarly, The Spearman’s correlations analyses shown that more of the colonic and cecal rather than the jejunal and the ileal bacterial species abundances were identified to be linked (P < 0.05) to the target pathway gene mRNA abundance responses in the weanling porcine growth performances [Figures 20 - 23], Verification of the weanling porcine study gut metagenomic DNA sample sizes and sequencing depth by the rarefaction curves

[0246] Rarefaction analyses using the non-redundant amplicon sequence variant (ASV) datasets were performed to verify whether the weanling porcine study gut metagenomic DNA sample sizes, which contained 18 and 16 of both the cecal digesta and the fecal samples for the control and the antimicrobials group, respectively, as well as the sequencing depth are sufficient for a thorough metagenomic analyses. Of the total 28356 ASV reads per sample, 4263 and 2503 ASV were identified from the cecal digesta samples; and 3419 and 3245 ASV were identified from the fecal samples for the control and antimicrobials group, respectively. Our results showed that the rarefaction curves were reaching their plateaus when the number of DNA samples extracted from cecal digesta and fecal samples for sequencing were increased [Figure 8(A) - (D)].

[0247] Furthermore, as shown in [Figure 10(A) and (B)], the rarefaction curves have flattened off when sequencing depth reached 28356 ASV reads per sample in our study. According to the results from three different estimators (i.e., Bootstrapping, Chao, and Jackknife) [Figure 10(C) and (D)], by which the species richness (i.e., the total number of species in that community) can be extrapolated from the observed data, antimicrobials significantly reduced (P < 0.05) species richness in the cecal digesta [Figure 10(C)] but did not change (P > 0.05) species richness in the fecal sample in comparison with the control [Figure 10 (D)].

[0248] Impacts of the therapeutic multi-antimicrobials on the characteristics of the weanling porcine cecal digesta and fecal microbiome

[0249] Dietary antimicrobials did not affect (P > 0.05) the estimates of total bacterial density and output in the cecal digesta and feces; however, antimicrobials tended to improve (P = 0.0573) the fecal total bacterial output compared to the control group. Moreover, the estimated bacteria density was higher (P < 0.05) in feces compared to cecal digesta in both control and antimicrobials group (Table 3).

[0250] Dietary antimicrobials decreased (P = 0.0173) the bacterial a-diversity endpoint of Chao-1 index in the cecal digesta [Figure 10(A)] and tended to reduce (P = 0.0790) Chao-1 index in the feces compared with the control [Figure 10(D)], No significant differences (P > 0.05) were observed on bacterial a-diversity endpoints of Shannon and Simpson index [Figure 9(A) and (C)] and [3-diversity [Figure 11(E)) and (F)] in both cecal digesta and feces between the two treatment groups.

[0251] Presently analyzed was the kingdom of Bacteria; the kingdoms of Archaea and Eukaryota were not determined. After removing the unidentified PCR chimera, the relative abundance (% to the total bacteria reads) of bacteria at the phylum, class, order, family, genus, and species level were calculated and compared between the control and antimicrobials groups. Overall, a total of 12 phyla, 20 classes, 30 orders, 52 families, 140 genera, and 257 species were identified in the cecal digesta, while a total of 19 phyla, 26 classes, 37 orders, 69 families, 183 genera, and 304 species were identified in the fecal samples by the Loop-Seq™ based high-resolution and high-accuracy synthetic full- length 16S-RNA gene sequencing platform. Of them, 4 phyla, 6 classes, 6 orders, 8 families, 35 genera and the data for the 53 species [Figure 14(A)] in the cecal digesta as well as 7 phyla, 8 classes, 8 orders, 11 families, 23 genera and the data for the 37 species [Figure 12(B)] in the fecal samples were identified with significant changes (P < 0.05) in their relative abundances between the control and the antimicrobials groups. The relative abundances of the cecal digesta and the fecal bacteria at order, family, genus, and species level that were not significantly modulated by antimicrobials in comparison with the control group were not shown here.

[0252] In the fecal samples [Figure 13(B)], of the 37 bacterial species identified with significant changes (P < 0.05), the antimicrobial administration resulted in enrichment of 8 but reduction of 29 bacterial species. The elevated species included potentially beneficial or probiotic bacterial species such as Holdemanella sp. in the class Erysipelotrichia and phylum and Lactococcus sp. in the class Bacilli and phylum Firmicutes as well as other bacterial species such as Dorea longicatena, Blautia obeum, and Defluviitaleaceae sp. in the class Clostridia and phylum Firmicutes, whereas the decreased species included zoonotic pathogens, such as Streptococcus orisratti in the class Bacilli and phylum Firmicutes; and Campylobacter lanienae and Campylobacter sp. in the class Campylobacteria and phylum Epsilonbacteraeota. Many other bacterial species were also decreased by dietary antimicrobials administration, such as Oribacterium sp., Lachnoclostridium sp., and Romboutsia sp. in the class Clostridia and phylum Firmicutes as well as Lactobacillus salivarius, Lactobacillus mucosae, and Lactobacillus ruminis m the class Bacilli and phylum Firmicutes (Figure 13B). Notably, the antimicrobial administration did not change (P > 0.05) the relative abundances of the bacterial species of Escherichia coli, Streptococcus suis and Lactobacillus sp. in the cecal digesta and fecal samples compared to the control group (data not shown here!). In addition, some of the notable opportunistic pathogenic bacterial species of Salmonella enterica and Clostridium perfringens were not detected in these study (data not shown).

[0253] Correlation and regression analyses between the weanling porcine cecal digesta and fecal microbiome and their gut health and growth performance endpoint responses

[0254] The Spearman’s correlations were conducted to identify specific bacterial species at the cecal digesta and the fecal level (Figure 19), as modulated by the dietary administration of the antimicrobials, associated with growth performances and nutrient (i.e., dietary sugars, starch, dietary fiber, and crude fat) utilization endpoints, i.e., nutrient digestibility. Our results showed that a total of 6, 3, and 5 bacterial species were positively associated with ADG, ADFI, and F:G, respectively, while a total of 8, 2, and 5 bacterial species were negatively associated with ADG, ADFI, and F:G, respectively, at the cecal digesta level (Figure 16). At the fecal level, a total of 1, 3 and 11 bacterial species showed positive correlations with ADG, ADFI, and F:G, respectively, whereas a total of 8, 1, and 1 bacterial species showed negative correlations with ADG, ADFI, and F:G, respectively (Figure 16). Of the significant correlations between fecal bacterial species and growth performance endpoints of ADG, ADFI, and F:G, we further conducted regression analyses to explore their simple linear and / or multiple linear relationships, which could serve as non-invasive microbiota-based biomarkers for the prediction of porcine growth performances. The results demonstrated that fecal bacterial species p-1088-a5 sp. and Parasutterella sp:, Defluviitaleaceae sp. and Parasutterella sp. as well as Selenomonas sp., Mitsuokella sp., Lachnoclostridium sp., and Streptococcus orisratti were selected as independent variable for the prediction of ADG [Table 5, Figure 24(A) and (B)], ADFI [Table 6, Figure 24(C) and (D)], and F:G [Table 7, Figure 24(E) - (H)], respectively. In addition, themultiple linear regression results suggested that the metric of the model performance (R2= 0.4225) was improved for the prediction of F:G by using the two bacterial special variables, i.e., fecal bacterial species of Selenomonas sp. and Streptococcus orisratti (Table 7). TABLE 2. Changes in the jejunal and ileal maltase-glucoamylase and sucrase- isomaltase activity kinetics of hydrolyzing maltose as well as the jejunal and ileal sucrase-isomaltase activity kinetics of hydrolyzing sucrose in the weanling pigs fed the experimental diet supplemented with therapeutic antimicrobials in comparison with the control diet for 3 weeks

[0255] ’Values are presented as LSMEANS ± SEM; for the jejunum, n = 12 and 9 independent maltose- and sucrose-hydrolytic kinetic experiments conducted with the corresponding weanling pig gut mucosal homogenates (1 pig from each pen) in the control and the antimicrobials’ group, respectively; and for the ileum, n = 13 and 11 independent maltose- and sucrose-hydrolytic kinetic experiments conducted with the corresponding weanling pig gut mucosal homogenates (1 pig from each pen) in the control and the antimicrobials’ group, respectively. Each maltose- and sucrose-hydrolytic kinetic experiment was conducted with 6 and 10 levels of the substrates, respectively, with each level in 3 replicates. The endpoint homogeneity variances were checked by using the Shapiro-Wilk tests. Differences of the endpoints between the two groups were conducted by the t-test and the two-way ANOVA procedures or the Kruskal-Wallis nonparametric comparisons procedure of SAS.2Km, the enzyme affinity, mmol-L1.

[0256] 3Vmax, the maximal enzyme activity, pmol-mg protein1-min1.

[0257] TABLE 3. Responses in the metagenomic DNA-based bacterial density and bacterial output estimates in cecal digesta and fecal samples in the weanling pigs fed the experimental diet supplemented with therapeutic antimicrobials in comparison with the control diet for 3 weeks

[0258] Item Control Antimicrobials Rvalue1

[0259] Bacterial density2

[0260] Cecal digesta 78.37 ± 4.44 80.66 ± 5.04 0.6048K

[0261] Feces 109.56 ± 7.66J 112.99 i 7.72f 0.5070

[0262] Bacterial output3

[0263] Cecal digesta 15.88 ± 1.39 16.42 ± 1.42 0.7887

[0264] Feces 16.28 ± 2.02 18.49 ± 2.31 0.1685

[0265] Bacterial output4

[0266] Cecal digesta 7.10 ± 0.52 8.13 ± 0.63 0.2828

[0267] Feces 7.56 ± 1.06 9.24 ± 1.32 0.0573

[0268] 'Values are presented as LSMEANS ± SEM; n = 18 and 16 pigs (1 pig from each pen) for both cecal digesta and fecal samples in the control and the antimicrobials’ group, respectively. The endpoint homogeneity variances were checked by using the Shapiro- Wilk tests. Differences of the endpoints between the two groups were conducted by the t-test and the two-way ANOVA procedures or the Kruskal-Wallis nonparametric comparisons procedure of SAS.

[0269] 2Bacterial density: total number of bacteria in trillions -kg1dry matter (DM) digesta or in trillions -kg fecal samples1.

[0270] 3Bacterial output: total number of bacteria in trillions -kg1DM diet intake.

[0271] 4Bacterial output: total number bacteria in trillions-pig '-d1, as calculated according to the digestibility marker technique.

[0272] KDifferences of the endpoint between the control and the antimicrobials groups were examined by the Kruskal-Wallis nonparametric comparisons procedure of SAS. ■j-Indicates significant difference (***p < 0.001) between the cecal digesta and fecal samples in the same experimental group that was compared by the t-test procedure of SAS.

[0273] Table 4. The simple linear relationships between the growth performance endpoints of the average daily gain (ADG) and the average feed intake (ADFI) and the plasma total alkaline phosphatase (AP) maximal enzyme activity (K-,,) in the weanling pigs fed the experimental diet and administered with therapeutic multi-antimicrobials in comparison with the control diet for 3 weeks Table 6. The simple and multiple linear relationships between the growth performance endpoint of the average daily feed intake (ADFI) and the significantly correlated fecal bacterial species' relative abundances (Vo of the total bacteria) in the weanling pigs fed the experimental diet and administered with the therapeutic multi-antimicrobials in comparison with the control diet for 3 weeks Table B. The simple and multiple linear relationships between the gut health response endpoint fecal score and the recal relative abundance of the bacterial multi-run ctional processrve GH5-p4818Cel5_2A gene (relative to the total

[0274] 16S rRNA gene) as well as the significantly correlated fecal bacterial species' relative abundances (% or" the total bacteria) in the weanling pigs red the experimental diet and administered with the therapeutic multi -antimicrobials in comparison with the control diet for 3 weeks

[0275] R d i t R i i S R*

[0276] Parameter estimates (± SE); and and probabilities for the parameter estimates o" the slope and the intercept, respectively, being significant at / < 0.05 (n = 34).

[0277] REFERENCES

[0278] Aghaali, M. & Hashemi-Nazari, S. S. Association between early antibiotic exposure and risk of childhood weight gain and obesity: A systematic review and meta-analysis. J. Pediatr. Endocrinol. Metab. 32, 439-445. https: / / doil0.1515 / ipem-2018-0437 (2019). Alauzet, C. et al. A New Look at the Genus Solobacteriunr. a retrospective analysis of twenty-seven cases of infection involving S’, moorei and a review of sequence databases and the literature. Microorganisms 9, 1229. https: / / doi.org / 10.3390 / microorganisms9061229 (2021).

[0279] Angelakis, E. et al. A metagenomic investigation of the duodenal microbiota reveals links with obesity. PloS ONE 10, e0137784. https: / / doi.org / 10.1371 / iournal.pone.0137784 (2015).

[0280] AOAC International. 2007. Official methods of analysis. 18th ed. AOAC Int., Washington, DC.

[0281] Aranaz, P., Ramos-Lopez, O., Cuevas-Sierra, A., Martinez, J. A., Milagro, F. I. & Riezu- Boj, J. I. A predictive regression model of the obesity-related inflammatory status based on gut microbiota composition. Int. J. Obes.M), 2261-2268. https: / / doi.org / 10.1038 / s41366-021-009Q4-4 (2021).

[0282] Arora, T., Vanslette, A. M., Hjorth, S. A. & Backhed, F. Microbial regulation of enteroendocrine cells. Med. 2, 553-570. https: / / doil0.1016 / j.medj.2021.03.018 (2021). Bach Knudsen, K. E., Laerke, H. N. & Jorgensen, H. Carbohydrates and carbohydrate utilization in Sustainable Swine Nutrition (1stedition Chiba, L. I.) 109-137. https: / / doil0.1002 / 9781118491454.ch5 (Wiley, 2012).

[0283] Bean-Hodgins, L. & Kiarie, E. G. Mandated restrictions on the use of medically important antibiotics in broiler chicken production in Canada: implications, emerging challenges, and opportunities for bolstering gastrointestinal function and health-a review. Can. J. Anim. Sci. 101, 602-629. https: / / doil0.1139 / cias-2021-0015 (2021). Beaumont, M. et al. Detrimental effects for colonocytes of an increased exposure to luminal hydrogen sulfide: The adaptive response. Free Radic. Biol. Med. 93, 155-164. https: / / doi.Org / 10.1016 / i.freeradbiomed.2016.01.028 (2016). Bergamaschi, M. et al. Gut microbiome composition differences among breeds impact feed efficiency in swine. Microbiome 8, 110. https: / / doi.Org / 10.l 186 / S40168-020- 00888-9 (2020).

[0284] Bokulich, N. A. et al. Antibiotics, birth mode, and diet shape microbiome maturation during early life. Sci. Transl. Med. 8, 343ra82. https: / / doi.Org / 10.l 126 / scitranslmed.aad7121 (2016).

[0285] Bonder, M. J. et al. The influence of a short-term gluten-free diet on the human gut microbiome. Genome Med. 8, 45. https: / / doi.Org / 10.l 186 / s 13073-016-0295-y (2016). Breton, J. et al. Gut commensal E. coli proteins activate host satiety pathways following nutrient-induced bacterial growth. Cell Metab. 23, 324-334. https: / / doil0.1016 / j.cmet.2015.10.017 (2016).

[0286] Butaye, P., Devriese, L. A. & Haesebrouck, F. Antimicrobial growth promoters used in animal feed: Effects of less well known antibiotics on gram-positive bacteria. Clin. Microbiol. Rev. 16, 175-188. https: / / doil0.1128 / CMR.16.2.175-188.2003 (2003).

[0287] Byrne, C. S., Chambers, E. S., Morrison, D. J. & Frost, G. The role of short chain fatty acids in appetite regulation and energy homeostasis. Int. J. Obes. 39, 1331-1338. https: / / doil0.1038 / ijo.2015.84 (2015).

[0288] Callahan, B. J. et al. High-throughput amplicon sequencing of the full-length 16S rRNA gene with single-nucleotide resolution. Nucleic Acids Res. 47, el03. https: / / doi.org / 10.1093 / nar / gkz569 (2019).

[0289] Callahan, B. J., Grinevich, D., Thakur, S., Balamotis, M. A. & Yehezkel, T. Ben. Ultra- accurate microbial amplicon sequencing with synthetic long reads. Microbiome 9, 130. https: / / doi.org / 10.1186 / s40168-021-01Q72-3 (2021).

[0290] CCAC (Canadian Council on Animal Care). Guide to the care and use of experimental animals. In: Olfert, E. D., Cross, B. M, McWilliam, A. A., editors. Ottawa, ON: CCAC; 1993.

[0291] CFIA (Canadian Food Inspection Agency). Compendium of medicating ingredient brochures until March 31, 2018. 2018. http: / / www.inspection.gc.ca / animals / feeds / medicatingingredients / eng / 130021260 0464 / 1320602461227 (accessed March 2022). Chandiwana, P. et al. Antenatal gut microbiome profiles and effect on pregnancy outcome in HIV infected and HIV uninfected women in a resource limited setting. BMC Microbiol. 23, 4. https: / / doi.org / 10.1186 / sl2866-022-02747-z (2023).

[0292] Chen, F., Hou, K. & Chen, Z. S. Gut microbes regulate the feeding center: a new discovery of Gut Brain Axis. Signal Transduct. Target. Ther. 7, 284. https: / / doil0.1038 / s41392-022-01117-5 (2022).

[0293] Chen, Y. J. et al. Parasutterella, in association with irritable bowel syndrome and intestinal chronic inflammation. J. Gastroenterol. Hepatol. 33, 1844-1852. https: / / doi.Org / 10.l 11 l / igh.14281 (2018).

[0294] Chiers, K., Haesebrouck, F., Mateusen, B., van Overbeke, I. & Ducatelle, R.

[0295] Pathogenicity of Actinobacillus minor, Actinobacillus indolicus and Actinobacillus porcinus strains for gnotobiotic piglets. J. Vet. Med. B. Infect. Dis. Vet. Public Health 48, 127-131. https: / / doi.Org / 10.1046 / j.1439-0450.2001.00433.x (2001).

[0296] Chimerel, C. et al. bacterial metabolite indole modulates incretin secretion from intestinal enteroendocrine L cells. Cell Rep. 9, 1202-1208. https: / / doil0.1016 / j.celrep.2014.10.032 (2014).

[0297] Coates, M. E., Fuller, R., Harrison, G. F., Lev, M. & Suffolk, S. F. A comparision of the growth of chicks in the Gustafsson germ-free apparatus and in a conventional environment, with and without dietary supplements of penicillin. J. Nutr. 17, 141-150. https: / / doil0.1079 / bjnl9630015 (1963).

[0298] Contijoch, E. J. et al. Gut microbiota density influences host physiology and is shaped by host and microbial factors. ELife, 8, e40553. https: / / doi.org / 10.7554 / elife.40553 (2019). Cox, L. M. & Blaser, M. J. Antibiotics in early life and obesity. Nat. Rev. Endocrinol. 11, 182-190. https: / / doil0.1038 / nrendo.2014.210 (2015).

[0299] Cremonesi, P., Biscarini, F., Castiglioni, B., Sgoifo, C. A., Compiani, R. & Moroni, P. Gut microbiome modifications over time when removing in-feed antibiotics from the prophylaxis of post-weaning diarrhea in piglets. PLoS ONE 17, e0262199. https: / / doi.org / 10.1371 / journal.pone.Q262199 (2022).

[0300] Cromwell, G. L. Why and how antibiotics are used in swine production. Anim.

[0301] Biotechnol. 13, 7-27. https: / / doil0.1081 / ABIQ-120005767 (2002).

[0302] Dahlqvist, A. Method for assay of intestinal disaccharidases. Anal. Biochem. 7, 18-25. https: / / doi.org / 10.1016 / 0003-2697(64)90115-0 (1964). Davrandi, M., Harris, S., Smith, P. J., Murray, C. D. & Lowe, D. M. The relationship between mucosal microbiota, colitis, and systemic inflammation in chronic granulomatous disorder. J. Clin. Immunol. 42, 312-324. https: / / doi.org / 10.10Q7 / sl0875-021-01165-6 (2022).

[0303] De Mille, C. M., Burrough, E. R., Kerr, B. J., Schweer, W. P. & Gabler, N. K. Dietary Pharmacological Zinc and Copper Enhances Voluntary Feed Intake of Nursery Pigs. Front. Anim. Sci. 3, 874284. https: / / doil0.3389 / fanim.2022.874284 (2022).

[0304] Dibner, J. J. & Richards, J. D. Antibiotic growth promoters in agriculture: History and mode of action. Poult. Sci. 84, 634-643. https: / / doi.Org / 10.1093 / PS / 84.4.634 (2005). Dolezel, J., Bartos, J., Voglmayr, H. & Greilhuber, J. Nuclear DNA content and genome size of trout and human. Cytometry 51A, 127-128. https: / / doi.Org / 10.1002 / cyto.a.10013 (2003).

[0305] Edgar, R. C. & Flyvbjerg, H. Error filtering, pair assembly and error correction for nextgeneration sequencing reads. Bioinformatics 31, 3476-3482. https: / / doi.org / 10.1093 / bioinformatics / btv401 (2015).

[0306] Enosi Tuipulotu, D., Mathur, A., Ngo, C. & Man, S. M. Bacillus cereus'. Epidemiology, virulence factors, and host-pathogen interactions. Trends Microbiol. 29, 458-471. https: / / doi.Org / 10.1016 / i.tim.2020.09.003 (2021).

[0307] Fan, M. Z. & Archbold, T. Novel and disruptive biological strategies for resolving gut health challenges in monogastric food animal production. Anim. Nutr. 1, 138-143. https: / / doil0.1016 / i.aninu.2015.10.002 (2015).

[0308] Fan, M. Z. & Sauer, W. C. Determination of true ileal amino acid digestibility in feedstuffs for pigs with the linear relationships between distal ileal outputs and dietary inputs of amino acids. J. Sci. Food. Agric. 73, 189-199. https: / / doi.org / 10.1002 / (SICI)1097-0010(199702)73:2<189::AID-JSFA702>3.0.CQ:2-N (1997).

[0309] Fan, M. Z. et al. Measuring synthesis rates of nitrogen-containing polymers by using stable isotope tracers. J. Anim. Sci. 84, E79-E93. https: / / doi.org / 10.2527 / 20Q6.8413 supplE79x (2006).

[0310] Fan, M. Z. et al. Novel methodology allows simultaneous measurement of true phosphorus digestibility and the gastrointestinal endogenous phosphorus outputs in studies with pigs. J. Nutr. 131, 2388-2396. https: / / doi.Org / 10.1093 / in / 131.9.2388 (2001).

[0311] Fan, M. Z. et al. Swine Nutrition and Environment in Sustainable Swine Nutrition (2ndedition Chiba, L. I.) 547-601 (Wiley, 2023a).

[0312] Fan, M. Z., Adeola, O., Asem, E. K. & King, D. Postnatal ontogeny of kinetics of porcine jejunal brush border membrane-bound alkaline phosphatase, aminopeptidase N and sucrase activities. Comp. Biochem. Physiol. A Mol. Integr. Physiol. 132, 599-607. https: / / doi.org / 10.1016 / sl095-6433(02)00102-2 (2002).

[0313] Fan, W. Therapeutic antimicrobials in modulation of gut health, growth performances, crude protein and amino acid utilization and gut microbiome in weanling pigs. Doctoral dissertation. University of Guelph, ON, Canada (2023).

[0314] Fernandez-Veledo, S. & Vendrell, J. Gut microbiota-derived succinate: Friend or foe in human metabolic diseases? Rev. Endocr. Metab. Disord. 20, 439-447. https: / / doi.org / 10.1007 / sl l l54-019-Q9513-z (2019).

[0315] Forbes, M., Park, J.T. Growth of germ-free and conventional chicks: effect of diet, dietary penicillin and bacterial environment. J. Nutr. 67, 69-84. https: / / doi.Org / 10.1093 / jn / 67.l.69 (1959).

[0316] Fouhse, J. M., Zijlstra, R. T. & Willing, B. P. The role of gut microbiota in the health and disease of pigs. Anim. Front. 6, 30-36. https: / / doi.org / 10.2527 / af.2016-0031 (2016).

[0317] Frost, G. et al. The short-chain fatty acid acetate reduces appetite via a central homeostatic mechanism. Nat. Commun. 5, 3611. https: / / doil0.1038 / ncomms4611 (2014).

[0318] Gabanyi, I. et al. Bacterial sensing via neuronal Nod2 regulates appetite and body temperature. Science 376, eabj3986. https: / / doil0.1126 / science.abj3986 (2022).

[0319] Galipeau, H. J. et al. Novel fecal biomarkers that precede clinical diagnosis of ulcerative colitis. Gastroenterology 160, 1532-1545. https: / / doi.Org / 10.1053 / j.gastro.2020.12.004 (2021).

[0320] Gardiner, G. E., Metzler-Zebeli, B. U. & Lawlor, P. G. Impact of intestinal microbiota on growth and feed efficiency in pigs: a review. Microorganisms 8, 1886. https: / / doi.org / 10.3390 / microorganisms8121886 (2020).

[0321] Gaskins, H. R., Collier, C. T. & Anderson, D. B. Antibiotics as growth promotants: Mode of action. Anim. Biotechnol. 13, 29-42. https: / / doil0.1081 / ABIQ-120005768 (2002). Greenhill, C. Gut microbiota: Proteins released by E. coli in the gut influence host appetite control. Nat. Rev. Endocrinol. 12, 4. https: / / doil0.1038 / nrendo.2015.213 (2016).

[0322] Gresse, R., Chaucheyras-Durand, F., Fleury, M. A., van de Wiele, T., Forano, E. & Blanquet-Diot, S. Gut microbiota dysbiosis in postweaning piglets: Understanding the keys to health. Trends Microbiol. 25, 851-873. https: / / doi.Org / 10.1016 / j.tim.2017.05.004 (2017).

[0323] Gresse, R., Durand, F. C., Duniere, L., Blanquet-Diot, S. & Forano, E. Microbiota composition and functional profiling throughout the gastrointestinal tract of commercial weaning piglets. Microorganisms 7, 343. https: / / doi.org / 10.3390 / microorganisms709Q343 (2019).

[0324] Gu, W. et al. Unaltered influenza disease outcomes in swine prophylactically treated with a-galactosylceramide. Dev. Comp. Immunol. 114, 103843. https: / / doi.Org / 10.1016 / j.dci.2020.103843 (2021).

[0325] Hacker, E., Antunes, C. A., Mattos-Guaraldi, A. L., Burkovski, A. & Tauch, A.

[0326] Corynebacterium ulcerans, an emerging human pathogen. Future Microbiol. 11, 1191— 1208. https: / / doi.org / 10.2217 / fmb-2016-0085 (2016).

[0327] Han, H. et al. From gut microbiota to host appetite: gut microbiota-derived metabolites as key regulators. Microbiome 9, 162. https: / / doil0.1186 / s40168-021-01093-y (2021). Hayhoe, M.-A. N., Archbold, T., Wang, Q., Yang, X. & Fan, M. Z. Prebiotics and p- Glucan as gut modifier feed additives in modulation of growth performance, protein utilization status and dry matter and lactose digestibility in weanling pigs. Front. Anim. Sci. 3, 855846. https: / / doi.org / 10.3389 / FANIM.2022.855846 (2022).

[0328] Helm, E. T., Curry, S., Trachselid, J. M., Schroyen, M. & Gablerid, N. K. Evaluating nursery pig responses to in-feed sub-therapeutic antibiotics. PLoS ONE 14, e0216070. https: / / doil0.1371 / journal.pone.0216070 (2019).

[0329] Henneke, L. et al. A dietary carbohydrate - gut Parasutterella - human fatty acid biosynthesis metabolic axis in obesity and type 2 diabetes. Gut Microbes 14, 2057778. https: / / doi.org / 10.1080 / 19490976.2022.2Q57778 (2022).

[0330] Hierowski, M. Inhibition of protein synthesis by chlortetracycline in the E. coli in vitro system. PNAS 53, 594-599. https: / / doi.Org / 10.1073 / pnas.53.3.594 (1965). Hill, E. M., Howard, C. D., Bale, T. L. & Jasarevic, E. Perinatal exposure to tetracycline contributes to lasting developmental effects on offspring. Anim. Microbiome 3, 37. https: / / doil0.1186 / s42523-021-00099-z (2021).

[0331] Holman, D. B., Chenier M. R. Temporal changes and the effect of subtherapeutic concentrations of antibiotics in the gut microbiota of swine. FEMS Microbiol. Ecol. 90, 599-608. https: / / doi.org / 10.l l l l / 1574-6941.12419 (2014).

[0332] Holmes, I. A. & Wild, D. G. Inhibition of the growth of Escherichia coli by chlortetracycline. Biochem J. 104, 679-685. https: / / doi.org / 10.1042 / bjlQ40679 (1967). Huang, Y. L. & Ma, Y. S. The effect of extrusion processing on the physiochemical properties of extruded orange pomace. Food Chem. 192, 363-369. https: / / doi.Org / 10.1016 / j.foodchem.2015.07.039 (2016).

[0333] Hvistendahl, M. Pigs as stand-ins for microbiome studies. Science 336, 1250, https: / / doi.Org / 10.l 126 / science.336.6086.1250 (2012).

[0334] Janczyk, P., Pieper, R., Souffrant, W. B., Bimczok, D., Rothkbtter, H. J. & Smidt, H.

[0335] Parenteral long-acting amoxicillin reduces intestinal bacterial community diversity in piglets even 5 weeks after the administration. ISME J. 1, 180-183. https: / / doi.org / 10.1038 / ismej.20Q7.29 (2007).

[0336] Jequier, E. Carbohydrates as a source of energy. Am. J. Clin. Nutr. 59, 682S-685S. https: / / doil0.1093 / AJCN / 59.3.682S (1994).

[0337] Ju, T., Kong, J. Y., Stothard, P. & Willing, B. P. Defining the role of Parasutterella, a previously uncharacterized member of the core gut microbiota. ISME J. 13, 1520-1534. https: / / doi.org / 10.1038 / s41396-019-0364-5 (2019).

[0338] Kaakoush, N. O., Castano-Rodriguez, N., Mitchell, H. M. & Man, S. M. global epidemiology of Campylobacter infection. Clin. Microbiol. Rev. 28, 687-720. https: / / doi.org / 10.1128 / CMR.000Q6-15 (2015).

[0339] Kellermayer, R. Roseburia species: Prime candidates for microbial therapeutics in inflammatory bowel disease. Gastroenterology 157, 1164-1165. https: / / doi.Org / 10.1053 / j.gastro.2019.05.073 (2019).

[0340] Kerr, B. J. et al. Evaluation of digestively resistant or soluble fibers, short-and mediumchain fatty acids, trace minerals, and antibiotics in nonchallenged nursery pigs on performance, digestibility, and intestinal integrity. J. Anim. Sci. 100, 1-19. https: / / doil0.1093 / jas / skac282 (2022). Kukuruzinska, M. A., and Lennon, K. Protein N-glycosylation: Molecular genetics and functional significance. Crit. Rev. Oral Biol. Med. 9, 415-448. https: / / doi.org / 10.1177 / 10454411980090040301 (1998).

[0341] Lackeyram, D. A. Expression of the small intestinal apical membrane hydrolases in the early-weaned piglet. Doctoral dissertation. University of Guelph, ON, Canada (2012). Lackeyram, D., Yang, C., Archbold, T., Swanson, K. C. & Fan, M. Z. Early weaning reduces small intestinal alkaline phosphatase expression in pigs. J. Nutr. 140, 461-468. https: / / doi.org / 10.3945 / jn.109.117267 (2010).

[0342] Laugerette, F., Pineau, G. Vors, C. & Michalski, M. C. Endotoxemia analysis by the limulus amoebocyte lysate assay in different mammal species used in metabolic studies. J. Anal. Bioanal. Tech. 6, 4 (2015). https: / / doi.10.4172 / 2155-9872.1000251.

[0343] Lalies, J. P. Luminal ATP: The missing link between intestinal alkaline phosphatase, the gut microbiota, and inflammation? Am. J. Physiol. Liver Physiol. 306, G824-G825. https: / / doi.org / 10.1152 / ajpgi.00435.2013 (2014).

[0344] Leeuwendaal, N. K., Cryan, J. F. & Schellekens, H. Gut peptides and the microbiome: focus on ghrelin. Curr. Opin. Endocrinol. Diabetes Obes. 28, 243-252. https: / / doi.org / 10.1097 / MED.000000000000Q616 (2021).

[0345] Li Y, Zhu Y, Wei H, Chen Y, Shang H. Study on the diversity and function of gut microbiota in pigs following long-term antibiotic and antibiotic-free breeding. Curr. Microbiol. 77, 4114-4128. https: / / doi.org / 10.1007 / s00284-020-0224Q-8 (2020).

[0346] Li, H. et al. Effects of several in-feed antibiotic combinations on the abundance and diversity of fecal microbes in weaned pigs. Can. J. Microbiol. 63, 402-410. https: / / doi.org / 10.1139 / cjm-2016-0681 (2017).

[0347] Li, Y., Cui, Y., Hu, X., Liao, X. & Zhang, Y. Chlorophyll supplementation in early life prevents diet-induced obesity and modulates gut microbiota in mice. Mol Nutr Food Res. 63, el801219. https: / / doi.org / 10.1002 / MNFR.2018Q1219 (2019).

[0348] Li, Y., Guo, Y., Wen, Z., Jiang, X., Ma, X. & Han, X. Weaning stress perturbs gut microbiome and its metabolic profile in piglets. Sci. Rep. 8, 18068. https: / / doi.org / 10.1038 / s41598-Q18-33649-8 (2018).

[0349] Liang, C. et al. Ligilactobacillus salivarius LCK11 prevents obesity by promoting PYY secretion to inhibit appetite and regulating gut microbiota in C57BL / 6J mice. Mol. Nutr. Food Res. 65, e2100136. https: / / doi.org / 10.1002 / mnfr.20210Q136 (2021a). Liang, J. Q. et al. A novel faecal Lachnoclostridium marker for the non-invasive diagnosis of colorectal adenoma and cancer. Gut 69, 1248-1257. https: / / doi.org / 10.1136 / gutjnl- 2019-318532 (2020).

[0350] Liang, J. Q. et al. Fecal microbial DNA markers serve for screening colorectal neoplasm in asymptomatic subjects. J. Gastroenterol. Hepatol. 36, 1035-1043. https: / / doi.Org / 10.l 111 / jgh.l 5171 (2021b).

[0351] Looft, T. et al. Bacteria, phages and pigs: the effects of in-feed antibiotics on the microbiome at different gut locations. ISME J. 8, 1566-1576. https: / / doi.org / 10.1038 / ismej.2014.12 (2014).

[0352] Looft, T. et al. In-feed antibiotic effects on the swine intestinal microbiome. PNAS 109, 1691-6. https: / / doi.org / 10.1073 / pnas.1120238109 (2012)

[0353] Lourenco, J. M., Hampton, R. S., Johnson, H. M., Callaway, T. R., Rothrock, M. J. & Azain, M. J. The effects of feeding antibiotic on the intestinal microbiota of weanling pigs. Front. Vet. Sci. 8, 601394. https: / / doi.org / 10.3389 / fvets.2021.601394 (2021). Luise, D. et al. The fecal microbiota of piglets during weaning transition and its association with piglet growth across various farm environments. PLoS ONE 16, e0250655. https: / / doi.org / 10.1371 / journal.pone.0250655 (2021).

[0354] Ma, T., McAllister, T. A. & Guan, L. L. A review of the resistome within the digestive tract of livestock. J. Anim. Sci. Biotechnol. 12, 121. https: / / doi.Org / 10.l 186 / s40104-021- 00643-6 (2021a).

[0355] McCormack, U. M. et al. Porcine feed efficiency-associated intestinal microbiota and physiological traits: finding consistent cross-locational biomarkers for residual feed intake. MSystems 4, e00324-18. https: / / doi.org / 10.1128 / mSystems.00324-18 (2019). McMurdie, P. J. & Holmes, S. phyloseq: An R package for reproducible interactive analysis and graphics of microbiome census data. PLoS ONE 8, e61217. https: / / doi.org / 10.1371 / journal.pone.0061217 (2013).

[0356] Meurens, F., Summerfield, A., Nauwynck, H., Saif, L. & Gerdts, V. The pig: A model for human infectious diseases. Trends Microbiol. 20, 50-57. https: / / doi.Org / 10.1016 / j.tim.2011.l l.002 (2012).

[0357] Morimoto, K., Watanabe, M., Sugizaki, T., Irie, J. I. & Itoh, H. Intestinal bile acid composition modulates prohormone convertase ip (PC 1 / 3) expression and consequent GLP-1 production in male mice. Endocrinology 157, 1071-1081. https: / / doil0.1210 / en.2015-1551 (2016).

[0358] Morton, E. R., Lynch, J., Froment, A., Lafosse, S., Heyer, E., Przeworski, M., Blekhman, R. & Segurel, L. Variation in rural African gut microbiota is strongly correlated with colonization by entamoeba and subsistence. PLoS Genet. 11, el 005658. https: / / doi.org / 10.1371 / iournal.pgen.1005658 (2015).

[0359] Myers, W. D., Ludden, P. A., Nayigihugu, V. & Hess, B. W. Technical note: a procedure for the preparation and quantitative analysis of samples for titanium dioxide. J. Anim. Sci. 82, 179-183. https: / / doi.org / 10.2527 / 2004.821179x (2004).

[0360] Nakatsuji, T. et al. Development of a human skin commensal microbe for bacteriotherapy of atopic dermatitis and use in a phase 1 randomized clinical trial. Nat. Med. 27, 700-709. https: / / doi.org / 10.1038 / s41591-021-01256-2 (2021).

[0361] Nayfach, S. & Pollard, K. S. Average genome size estimation improves comparative metagenomics and sheds light on the functional ecology of the human microbiome. Genome Biol. 16, 51. https: / / doi.org / 10.1186 / S13059-015-0611-7 (2015).

[0362] Neuman, H., Forsythe, P., Uzan, A., Avni, O. & Koren, O. Antibiotics in early life: dysbiosis and the damage done. FEMS Microbiol. Rev. 42, 489-499. https: / / doi.org / 10.1093 / femsre / fuy018 (2018).

[0363] Nichols, B. L. et al. The maltase-glucoamylase gene: Common ancestry to sucrase- isomaltase with complementary starch digestion activities. PNAS 100, 1432-1437. https: / / doi.org / 10.1073 / pnas.023717010Q (2002).

[0364] National Research Council (NRC). Nutrient requirements of swine. 11th ed. National Academics Press, Washington, DC. (2012).

[0365] National Research Council (NRC). Nutrient requirements of swine. 10th ed. National Academics Press, Washington, DC. (1998).

[0366] Patel, S. J., Wellington, M., Shah, R. M. & Ferreira, M. J. Antibiotic stewardship in foodproducing animals: challenges, progress, and opportunities. Clin. Ther. 42, 1649-1658. https: / / doi.Org / 10.1016 / j.clinthera.2020.07.004 (2020).

[0367] Pichette, J., Fynn-Sackey, N. & Gagnon, J. Hydrogen sulfide and sulfate prebiotic stimulates the secretion of GLP-1 and improves glycemia in male mice. Endocrinology 158, 3416-3425. https: / / doil0.1210 / en.2017-00391 (2017). Poole, T. L., Suchodolski, J. S., Callaway, T. R., Farrow, R. L., Loneragan, G. H. & Nisbet, D. J. The effect of chlortetracycline on faecal microbial populations in growing swine. J. Glob. Antimicrob. Resist. 1, 171-174. https: / / doi.Org / 10.1016 / i.igar.2013.04.004 (2013).

[0368] Prestinaci, F., Pezzotti, P. & Pantosti, A. Antimicrobial resistance: a global multifaceted phenomenon. Pathog. Glob. Heal. 109, 309-318. https: / / doi 10.1179 / 2047773215Y.0000000030 (2015).

[0369] Quan, J. et al. A global comparison of the microbiome compositions of three gut locations in commercial pigs with extreme feed conversion ratios. Sci. Rep. 8, 4536. https: / / doi.org / 10.1038 / s41598-018-22692-0 (2018).

[0370] Quan, J. et al. Exploring the fecal microbial composition and metagenomic functional capacities associated with feed efficiency in commercial DLY pigs. Front. Microbiol. 10, 52 https: / / doi.org / 10.3389 / fmicb.2019.00Q52 (2019).

[0371] Quan, J. et al. Metagenomic characterization of intestinal regions in pigs with contrasting feed efficiency. Front. Microbiol. 11, 32. https: / / doi.org / 10.3389 / fmicb.2020.00Q32 (2020).

[0372] Rasmussen, S. H. et al. Antibiotic exposure in early life and childhood overweight and obesity: A systematic review and meta-analysis. Diabetes Obes. Metab. 20, 1508-1514. https: / / doi 10.1111 / dom.13230 (2018).

[0373] Razali, N. M. & Wah, Y. B. Power comparisons of Shapiro-Wilk, Kolmogorov-Smirnov, Lilliefors and Anderson-Darling tests. J. Stat. Model. Anal. 2, 21-33. (2011).

[0374] Reily, C., Stewart, T. J., Renfrow, M. B., and Novak, J. Glycosylation in health and disease. Nat. Rev. Nephrol. 15, 346-366. https: / / doi.org / 10.1038 / s41581-019-0129-4 (2019).

[0375] Ren, L., Qin, X., Cao, X., Wang, L., Bai, F., Bai, G. & Shen, Y. Structural insight into substrate specificity of human intestinal maltase-glucoamylase. Protein Cell 2, 827-836. https: / / doi.org / 10.10Q7 / S13238-011-1105-3 (2011).

[0376] Reyman, M. et al. Effects of early-life antibiotics on the developing infant gut microbiome and resistome: a randomized trial. Nat. Commun. 13, 893. https: / / doi.org / 10.1038 / s41467-Q22-28525-z (2022).

[0377] Rideout, T. C., Q. Liu, P. Wood, and M. Z Fan. Nutrient utilization and intestinal fermentation are differentially affected by the consumption of resistant starch varieties and conventional fibers in pigs. Br. J. Nutr. 99, 984-992. https: / / doi.org / 10.1017 / SQ007114507853396 (2008). Rodriguez-Romero, J. de J. et al. What we know about protein gut metabolites:

[0378] Implications and insights for human health and diseases. Food Chem. X 13, 100195. https: / / doil0.1016 / j.fochx.2021.100195 (2022).

[0379] Romani-Perez, M. et al. The microbiota and the gut-brain axis in controlling food intake and energy homeostasis. Int. J. Mol. Sci. 22, 5830. https: / / doil0.3390 / iims22115830 (2021).

[0380] Rose, E. C., Blikslager, A. T. & Ziegler, A. L. Porcine models of the intestinal microbiota: the translational key to understanding how gut commensals contribute to gastrointestinal disease. Front. Vet. Sci. 9, 834598. https: / / doi.org / 10.3389 / fvets.2022.834598 (2022).

[0381] Rowan, F., Docherty, N. G., Murphy, M., Murphy, B., Coffey, J. C. & O’Connell, P. R.

[0382] Desulfovibrio bacterial species are increased in ulcerative colitis. Dis. Colon. Rectum 253, 1530-1536. https: / / doi.org / 10.1007 / dcr.0b013e3181fle62Q (2010).

[0383] Santos, E. d. O. & Thompson, F. The family Succinivibrionaceae in The Prokaryotes: Gammaproteobacteria (Rosenberg, E. et al.) 639-648 https: / / doi.org / 10.10Q7 / 978-3-642- 38922-1 368 (Springer, 2014).

[0384] Shao, X. et al. Antibiotic exposure in early life increases risk of childhood obesity: A systematic review and meta-analysis. Front. Endocrinol. 8, 170. https: / / doil0.3389 / fendo.2017.00170 (2017).

[0385] Sim, L., Quezada-Calvillo, R., Sterchi, E. E., Nichols, B. L. & Rose, D. R. Human intestinal maltase-glucoamylase: crystal structure of the N-terminal catalytic subunit and basis of inhibition and substrate specificity. J. Mol. Biol. 375, 782-792. https: / / doi.Org / 10.1016 / j.jmb.2007.10.069 (2008).

[0386] Sim, L., Willemsma, C., Mohan, S., Naim, H. Y., Pinto, B. M. & Rose, D. R. Structural basis for substrate selectivity in human maltase-glucoamylase and sucrase-isomaltase N- terminal domains. J. Biol. Chem. 285, 17763-17770. https: / / doi.org / 10.1074 / jbc.M109.07898Q (2010).

[0387] Slade, E., Williams, L. & Gagnon, J. Hydrogen sulfide suppresses ghrelin secretion in vitro and delays postprandial ghrelin secretion while reducing appetite in mice. Physiol. Rep. 6, el3870. https: / / doil0.14814 / phy2.13870 (2018). Stein, H. H., Seve, B., Fuller, M. F., Moughan, P. J. & de Lange, C. F. M. Invited review: Amino acid bioavailability and digestibility in pig feed ingredients: terminology and application. J. Anim. Sci. 85, 172-180. https: / / doi.org / 10.2527 / ias.20Q5-742 (2007). Szancer, J. Minimal inhibitory concentrations of antimicrobial agents against Actinobacillus pleuropneumoniae. Can. J. Vet. Res. 54, 198-199. (1990).

[0388] Tan, 7,.et al. Metagenomic analysis of cecal microbiome identified microbiota and functional capacities associated with feed efficiency in Landrace finishing pigs. Frontiers in Microbiology, 8, 1546. https: / / doi.org / 10.3389 / fmicb.2017.Q1546 (2017).

[0389] Tanaka, S. etal. Influence of antibiotic exposure in the early postnatal period on the development of intestinal microbiota. FEMS Immunol. Med. Microbiol. 56, 80-87 https: / / doi.Org / 10.l l l l / j.1574-695X.2009.00553.x (2009)

[0390] Thiex, N. J., Anderson, S., Gildemeister, B. & Collaborators. Crude fat, diethyl ether extraction, in feed, cereal grain, and forage (randall / soxtec / submersion method): collaborative study. J AOAC Int. 86, 888-898. https: / / doi.Org / 10.1093 / iaoac / 86.5.888 (2003).

[0391] Tolhurst, G. et al. Short-chain fatty acids stimulate glucagon-like peptide-1 secretion via the G-protein-coupled receptor FFAR2. Diabetes 61, 364-371. https: / / doilO.2337 / dbl 1- 1019 (2012).

[0392] Vacca, M., Celano, G., Calabrese, F. M., Portincasa, P., Gobbetti, M. & de Angelis, M. The controversial role of human gut Lachnospiraceae. Microorganisms 8, 573. https: / / doi.org / 10.3390 / microorganisms8040573 (2020).

[0393] Valido, E. et al. Systematic review of the changes in the microbiome following spinal cord injury: animal and human evidence. Spinal Cord 60, 288-300. https: / / doi.org / 10.1038 / s41393-021-0Q737-y (2022).

[0394] Vallianou, N., Dalamaga, M., Stratigou, T., Karampela, I. & Tsigalou, C. Do antibiotics cause obesity through long-term alterations in the gut microbiome? A review of current evidence. Curr. Obes. Rep. 10, 244-262. https: / / doil0.1007 / sl3679-021-00438-w (2021). Van Boeckel, T. P. et al. Global trends in antimicrobial use in food animals. PNAS 112, 5649-5654. https: / / doil0.1073 / pnas.1503141112 (2015).

[0395] Vancanneyt, M. et al. Enterococcus villorum sp. nov., an enteroadherent bacterium associated with diarrhoea in piglets. Int. J. Syst. Evol. Microbiol. 51, 393-400. https: / / doi.org / 10.1099 / 002Q7713-51-2-393 (2001). Wang, J. et al. Investigation of the genomic and pathogenic features of the potentially zoonotic streptococcus parasuis. Pathogens 10, 834. https: / / doi.org / 10.3390 / pathogensl0070834 (2021b).

[0396] Wang, M. et al. Genetic characterization, mechanisms and dissemination risk of antibiotic resistance of multidrug-resistant Rothia nasimurium. Infect. Genet. Evol. 90, 104770. https: / / doi.Org / 10.1016 / i.meegid.2021.104770 (2021a).

[0397] Wang, W., Hu, H., Zijlstra, R. T., Zheng, J. & Ganzle, M. G. Metagenomic reconstructions of gut microbial metabolism in weanling pigs. Microbiome 7, 48. https: / / doi.org / 10.1186 / s40168-019-0662-l (2019a)

[0398] Wang, X. et al. Longitudinal investigation of the swine gut microbiome from birth to market reveals stage and growth performance associated bacteria. Microbiome 7, 109. https: / / doi.org / 10.1186 / s40168-019-0721-7 (2019b).

[0399] WHO (World Health Organization). Campylobacter Fact Sheets. 2020. https: / / www.who.int / news-room / fact-sheets / detail / campylobacter (accessed March 2023).

[0400] Williams, H. E. et al. Effects of chlortetracycline alone or in combination with direct fed microbials on nursery pig growth performance and antimicrobial resistance of fecal Escherichia coli. J. Anim. Sci. 96, 5166-5178. https: / / doil0.1093 / ias / sky370 (2018). Williams, L., Alshehri, A., Robichaud, B., Cudmore, A. & Gagnon, J. The role of the bacterial muramyl dipeptide in the regulation of GLP-1 and glycemia. Int. J. Mol. Sci. 21, 5252. https: / / doil0.3390 / iims21155252 (2020).

[0401] Wilson, B. A. & Ho, M. Pasteurella multocida'. from zoonosis to cellular microbiology. Clin. Microbiol. Rev. 26, 631-655. https: / / doi.org / 10.1128 / CMR.00024-13 (2013). Yang, C. et al. Apical Na+-D-glucose cotransporter 1 (SGLT1) activity and protein abundance are expressed along the jejunal crypt-villus axis in the neonatal pig. Am. J. Physiol. Gastrointest. Liver Physiol. 300, G60-70. https: / / doi.org / 10.1152 / ajpgi.00208.201Q (2011).

[0402] Yassour, M. et al. Natural history of the infant gut microbiome and impact of antibiotic treatments on strain-level diversity and stability. Sci. Transl. Med. 8, 343ra81. https: / / doi.Org / 10.l 126 / scitranslmed.aad0917 (2016). Yazdankhah, S., Rudi, K. & Bernhoft, A. Zinc and copper in animal feed - development of resistance and co-resistance to antimicrobial agents in bacteria of animal origin. Microb. Ecol. Heal. Dis. 25, 25862. https: / / doil0.3402 / mehd.v25.25862 (2014).

[0403] Yeh, T. K., Lin, H. J., Liu, P. Y., Wang, J. H. & Hsueh, P. R. Antibiotic resistance in Enterobacter hormaechei. Int. J. Antimicrob. Agents 60, 106650. https: / / doi.Org / 10.1016 / i.iiantimicag.2022.106650 (2022).

[0404] Yin X. Nutritional and genomic factors affecting gut alkaline phosphatase functionality in weanling pigs. Doctoral dissertation. University of Guelph, ON, Canada (2021).

[0405] Yin, X., Wang, W., Seah, S. Y. K., Mine, Y. & Fan, M. Z. Deglycosylation differentially regulates weaned porcine gut alkaline phosphatase isoform functionality along the longitudinal axis. Pathogens. 12, 407. https: / / doi.org / 10.3390 / pathogensl20304Q7 (2023).

[0406] Yoon, H. S. et al. Akkermansia muciniphila secretes a glucagon-like peptide-l-inducing protein that improves glucose homeostasis and ameliorates metabolic disease in mice. Nat. Microbiol. 6, 563-573. https: / / doilO.1038 / s41564-021-00880-5 (2021).

[0407] Yu, J. et al. Metagenomic analysis of faecal microbiome as a tool towards targeted non- invasive biomarkers for colorectal cancer. Gut 66, 70-78. https: / / doi.org / 10.1136 / gutinl-2015-309800 (2017b).

[0408] Yu, M. et al. Long-term effects of early antibiotic intervention on blood parameters, apparent nutrient digestibility, and fecal microbial fermentation profile in pigs with different dietary protein levels. J. Anim. Sci. Biotechnol. 8, 60. https: / / doil0.1186 / s40104-017-0192-2 (2017a).

[0409] Yutin, N. & Galperin, M. Y. A genomic update on clostridial phylogeny: Gram-negative spore formers and other misplaced Clostridia. Environ. Microbiol. 15, 2631-2641. https: / / doi.org / 10.l l l l / 1462-2920.12173 (2013).

[0410] Zambom de Souza, A. Z. et al. Oral supplementation with L-glutamine alters gut microbiota of obese and overweight adults: A pilot study. Nutrition 31, 884-889. https: / / doi.Org / 10.1016 / j.nut.2015.01.004 (2015).

[0411] Zhang, Y., Tan, L., Li, C., Wu, H., Ran, D. & Zhang, Z. Sulforaphane alter the microbiota and mitigate colitis severity on mice ulcerative colitis induced by DSS. AMB Express 10, 119. https: / / doi.org / 10.1186 / sl3568-020-01Q53-z (2020). Zhang, Y.L. et al. Gut microbiota contributes to the distinction between two traditional Chinese medicine syndromes of ulcerative colitis. World J. Gastroenterol. 25, 3242-3255. https: / / doi.org / 10.3748 / wig.v25.i25.3242 (2019).

[0412] Zhao, L., Zhang, Q., Ma, W., Tian, F., Shen, H. & Zhou, M. A combination of quercetin and resveratrol reduces obesity in high-fat diet-fed rats by modulation of gut microbiota. Food Fund. 8, 4644-4656. https: / / doi.org / 10.1039 / c7fo01383c (2017).

[0413] The invention has been described in an illustrative manner, and it is to be understood that the terminology, which has been used is intended to be in the nature of words of description rather than of limitation.

[0414] Modifications and variations of the present invention are possible in light of the above teachings. It is, therefore, to be understood that within the scope of the appended claims, the invention can be practiced otherwise than as specifically described.

Claims

Claims:

1. A method using a combination of a metabolomic biomarker and a metagenomic biomarker for the assessment and / or monitoring of health performance of an animal, the method comprising: obtaining a physiological sample from the animal, wherein the sample is blood, serum or plasma, and conducting an assay to determine alkaline phosphatase (pALP) activity as the metabolomic biomarker that provides an indication of the animal’s relative health performance.

2. The method of claim 1, wherein the health performance comprises the prediction and / or assessment of average daily weight gain and average feed intake of the animal.

3. The method of claim 1 or 2, wherein the health performance further comprises diagnosis and / or prediction of gut health (fecal score) and feed conversion efficiency in the animal.

4. The method of claim 4, wherein the gut health is determined by collecting a fecal sample from the animal and determining levels of GH5-p4818Cel5_2A endocellulase gene relative to total 16S rRNA.

5. The method of claim 3 or 4, wherein feed conversion efficiency of the animal is performed by determining fecal relative abundances of one or more of Blautia obeum, Oribacterium sp., Lactobacillus salivarius, p-2534-18B5 sp., dgA-11 sp., Mucispirillum sp. and Streptococcus orisratti .

6. The method according to any one of claims 1 to 5, further comprising determining endotoxin activity of plasma, endotoxin activity of cecal digesta and / or fecal endotoxin activity of the animal as a further indicator of health performance of the animal.

7. The method according to any one of claims 1 to 6, wherein the animal is receiving antimicrobial treatment.

8. The method according to claim 7, wherein the health performance is assessed and / or monitored compared to a control animal not receiving antimicrobial treatment.

9. The method according to any one of claims 1 to 8, wherein the animal is undergoing stress and / or disease challenge.

10. The method according to any one of claims 1 to 9, wherein the animal is weaning.

11. The method according to any one of claims 1 to 10, wherein the animal is a livestock animal or a companion animal.

12. The method of claim 11, wherein the animal is a pig.

13. The method according to any one of claims 10 to 12, wherein the animal is a pig or a weaning piglet.

14. A method for identifying and / or monitoring health performance of an animal comprising collecting a sample from the animal, and assaying alkaline phosphatase (pALP) activity as an indication of the animal’s relative health performance.

15. The method of claim 14, wherein the animal is receiving antimicrobial treatment and the pALP activity is increased compared to a control.

16. The method of claim 15, wherein the control is an animal not receiving antimicrobial treatment.

17. The method according to claim 15 or 16, wherein an increase in pALP activity is relative to a control animal, optionally the control animal is receiving antimicrobial treatment.

18. A method for determining fecal score (gut health status) comprising collecting a fecal sample from the animal, and determining expression levels of GH5-p4818Cel5_2A endocellulase gene relative to total 16S rRNA, wherein increased expression levels indicate the animal’s gut health status is healthy.

19. The method of claim 18, wherein the animal is receiving antimicrobial treatment and the expression levels are compared to a control.

20. The method of claim 19, wherein the control is an animal not receiving antimicrobial treatment.

21. The method according to claim 19 or 20, wherein an increase in the expression levels of GH5-p4818Cel5_2A endocellulase gene relative to total 16S rRNA, is compared to a control animal, optionally the control animal is receiving antimicrobial treatment.

22. A method for predicting average daily weight gain, average feed intake and feed conversion efficiency of an animal, the method comprising collecting a fecal sample from the animal, determining fecal relative abundances of one or more of Blautia obeum,Oribacterium sp., Lactobacillus salivarius, p-2534-18B5 sp., dgA-11 sp., Mucispirillum sp. and Streptococcus orisratti and determining or predicting the animals gut health, wherein increased expression of one or more of Blautia obeum, Oribacterium sp., Lactobacillus salivarius, p-2534-18B5 sp., dgA-11 sp., Mucispirillum sp. and Streptococcus orisratti indicates a healthy animal.

23. A method for predicting growth performance of an animal comprising collecting a fecal sample from the animal, determining levels of specific fecal bacterial species relative to total 16rRNA genes in the sample, and determining the animal’s growth performance.

24. The method of claim 23, wherein the growth performance comprises average daily weight gain, average feed intake and feed conversion efficiency.

25. The method of claims 23 or 24, wherein the fecal bacterial species are one or more of p-1088-a5 sp., Parasutterella sp., Defluviitaleaceae sp., Parasutterella sp.; Selenomonas sp., Mitsuokella sp., Lachnoclostridium sp. and Streptococcus orisratti.

26. The method of any one of claims 22 to 25, wherein the animal is a pig.

27. The method of any one of claims 22 to 26, wherein the animal is a weanling.

28. The method of any one of claims 22 to 27, wherein the animal is a weanling piglet.

29. A component of a kit for determining and monitoring health performance of an animal, the component comprising a means for determining the extent of expression / activity of plasma alkaline phosphatase (pALP) as a metabolomic biomarker for health performance, wherein the alkaline phosphatase activity exhibits a substantial correlation to average daily body weight gain and daily feed intake of an animal as an indication of health performance.

30. The component of claim 29, wherein the pALP substantially correlates to jejunal maximal alkaline phosphatase activity of said animal and is predictive of body weight gain and voluntary feed intake of the animal.

31. A component of a kit for determining gut health of an animal, the component comprising a means for determining in a fecal sample from the animal levels of GH5- p4818Cel5_2A endocellulase gene (fGH5) as a biomarker relative to total 16S rRNA, wherein the biomarker exhibits a substantial correlation to gut health endpoint of an animal.

32. A fecal metagenomic biomarker panel for assessing gut health of an animal, the panel comprising isolated fecal bacterial species that exhibit a substantial correlation to gut health status as well as growth performance endpoints of average daily gain, average feed intake and feed conversion efficiency of an animal, wherein the bacterial species comprises one or more of Blautia obeum, Oribacterium sp., Lactobacillus salivarius, p-2534-18B5 sp., dgA-11 sp., Mucispirillum sp. and Streptococcus orisratti.

33. A kit for predicting daily body weight gain and daily feed intake in an animal, the kit comprising reagent(s) / substrate(s) for measuring serum pALP activity, and optionally a control sample and / or instructions..

34. A kit for predicting fecal score in an animal, the kit comprising: reagent(s) / substrate(s) for measuring fGH5 abundance (levels), and optionally a control sample and / or instructions.

35. A kit for predicting overall gut health status as well as growth performance endpoints of average daily gain, average feed intake and feed conversion efficiency in an animal, the kit comprising reagents for measuring a panel of fecal bacterial species and optionally a control sample and / or instructions for use, wherein the fecal bacterial species comprises at least one of Blautia obeum, Oribacterium sp., Lactobacillus salivarius, p-2534-18B5 sp., dgA-11 sp., Mucispirillum sp. and Streptococcus orisratti.

30. Use of plasma alkaline phosphatase (pALP) as a serum metabolomic biomarker predictive of average daily body weight gain and daily feed intake of an animal, preferably a weanling piglet.

31. Use of fGH5 as a metagenomic fecal biomarker that exhibits a substantial correlation to gut health endpoint of an animal.

32. Use of specific fecal bacterial species levels as a metagenomic biomarker panel for predicting overall gut health status of an animal, preferably the fecal bacterial species comprises one or more of p-1088-a5 sp., Parasutterella sp., Defluviitaleaceae sp., Parasutterella sp.; Selenomonas sp., Mitsuokella sp., Lachnoclostridium sp. and Streptococcus orisratti, and preferably the animal is a weanling piglet.